var title_f4_42_4768="Staging of patients who meet the definition of CKD";
var content_f4_42_4768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Staging of patients who meet the definition of CKD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 444px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    GFR and albuminuria grid to reflect the risk of progression by intensity of coloring (green, yellow, orange, red, deep red). The numbers in the boxes are a guide to the frequency of monitoring (number of times per year).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Kidney International. KDIGO. Summary of recommendation statements. Kidney Int 2013; 3(Suppl):5. Copyright &copy; 2013.",
"     <a href=\"file://www.nature.com/ki/index.html\" target=\"_blank\">",
"      file://www.nature.com/ki/index.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4768=[""].join("\n");
var outline_f4_42_4768=null;
var title_f4_42_4769="Ulcerations and gangrene in thromboangiitis obliterans";
var content_f4_42_4769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulcerations and gangrene in thromboangiitis obliterans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berg, D, Worzala, K. Atlas of Adult Physical Diagnosis. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4769=[""].join("\n");
var outline_f4_42_4769=null;
var title_f4_42_4770="Patient information: Severe Acute Respiratory Syndrome (SARS) (The Basics)";
var content_f4_42_4770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/55/18291\">",
"         Patient information: Cough, runny nose, and the common cold (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/12/35013\">",
"         Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/11/44210\">",
"         Patient information: The common cold in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Severe Acute Respiratory Syndrome (SARS) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/severe-acute-respiratory-syndrome-sars-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6662797\">",
"      <span class=\"h1\">",
"       What is severe acute respiratory syndrome (SARS)?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Severe acute respiratory syndrome (also called SARS) is an infection caused by a virus. It causes fever, cough, and other symptoms. SARS can also cause serious lung problems and even death. There were outbreaks of SARS in 2003 and 2004, mostly in China and other countries in Asia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662812\">",
"      <span class=\"h1\">",
"       What are the symptoms of SARS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms are different depending on how long it has been since a person was exposed to the virus.",
"     </p>",
"     <p>",
"      At first, the symptoms of SARS include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A fever higher than 100.5&ordm;F (38&ordm;C), often with chills, shaking, or both",
"       </li>",
"       <li>",
"        Feeling sick, like you have the flu",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Muscle aches",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The first SARS symptoms usually last 3 to 7 days. After that, symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Dry cough",
"       </li>",
"       <li>",
"        Shortness of breath &ndash; People with SARS often feel like they cannot take a deep breath or get enough air. Some people feel like their chest is tight or they have to work harder than usual to breathe.",
"       </li>",
"       <li>",
"        Chest pain when coughing or breathing &nbsp;",
"       </li>",
"       <li>",
"        Diarrhea",
"       </li>",
"       <li>",
"        Sore throat",
"       </li>",
"       <li>",
"        Runny nose",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For the first 3 to 7 days of SARS, most people do not have a cough, breathing problems, runny nose, or sore throat even if they have a fever and feel sick. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662826\">",
"      <span class=\"h1\">",
"       Is there a test for SARS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can test for the virus that causes SARS. Tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lab tests on a sample of mucus from your nose",
"       </li>",
"       <li>",
"        Lab tests on a sample of your bowel movement",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor can also do a chest X-ray to look for signs of SARS. If the chest X-ray does not show anything and your doctor still thinks you might have SARS, he or she might do an imaging test called a CT scan. A CT scan creates a sharper image of the inside of your body than an X-ray. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662841\">",
"      <span class=\"h1\">",
"       Is SARS dangerous?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It can be. Most people who get SARS need to go to the hospital. Some people even die from it. That&rsquo;s because SARS can cause serious lung damage.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662858\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if there is an outbreak of SARS and:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have trouble breathing.",
"       </li>",
"       <li>",
"        You have a cough with a fever of 100.5&ordm;F (38&ordm;C) or higher, chest pain, or both.",
"       </li>",
"       <li>",
"        You think you were near someone with SARS, for example, on an airplane or in a country affected by an outbreak.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662873\">",
"      <span class=\"h1\">",
"       How is SARS treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with SARS are treated in the hospital, sometimes in the intensive care unit (ICU). Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines and other treatments to reduce pain, breathing problems, diarrhea, and other symptoms",
"       </li>",
"       <li>",
"        Using a ventilator (breathing machine), if you have trouble breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      So far, doctors do not have a good medicine to fight the virus that causes SARS. There are medicines called &ldquo;antiviral&rdquo; medicines that help fight other viruses, such as the virus that causes the flu. But those antiviral medicines do not work well on SARS. Antibiotics DO NOT WORK on SARS. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662888\">",
"      <span class=\"h1\">",
"       Can SARS be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting SARS by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        NOT going to areas where there is an outbreak of SARS",
"       </li>",
"       <li>",
"        NOT eating certain foods (such as meat from unusual animals) if you travel or live in Asia &nbsp;",
"       </li>",
"       <li>",
"        Wearing a mask, hospital gown, and gloves and washing your hands if you are around someone with SARS",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662903\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=see_link\">",
"       Patient information: Cough, runny nose, and the common cold (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"       Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44210?source=see_link\">",
"       Patient information: The common cold in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/42/4770?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17201 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4770=[""].join("\n");
var outline_f4_42_4770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662797\">",
"      What is severe acute respiratory syndrome (SARS)?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662812\">",
"      What are the symptoms of SARS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662826\">",
"      Is there a test for SARS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662841\">",
"      Is SARS dangerous?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662858\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662873\">",
"      How is SARS treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662888\">",
"      Can SARS be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662903\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=related_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44210?source=related_link\">",
"      Patient information: The common cold in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_42_4771="Computed tomography of appendicitis in a child";
var content_f4_42_4771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Computed tomography of appendicitis in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT of the pelvis following administration of intravenous contrast material in an 8-year-old boy with midline pelvic pain, fever, and leucocytosis shows an enlarged, fluid filled, abnormally enhancing appendix and associated mesenteric inflamation to the left of midline (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George A Taylor, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4771=[""].join("\n");
var outline_f4_42_4771=null;
var title_f4_42_4772="Pulm AVM PA gram I";
var content_f4_42_4772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arteriovenous malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pulmonary arteriogram shows an arteriovenous malformation supplied by a pulmonary artery branch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4772=[""].join("\n");
var outline_f4_42_4772=null;
var title_f4_42_4773="Ezetimibe: Drug information";
var content_f4_42_4773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ezetimibe: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/57/19348?source=see_link\">",
"    see \"Ezetimibe: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17844?source=see_link\">",
"    see \"Ezetimibe: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zetia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ezetrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F169589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, 2-Azetidinone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F169570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hyperlipidemias, sitosterolemia:",
"     </b>",
"     Oral: 10 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F169583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17844?source=see_link\">",
"      see \"Ezetimibe: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;10 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F169571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F169572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     AUC increased with severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); no dosing adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F169573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     AUC increased with hepatic impairment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild impairment (Child-Pugh class A): No dosing adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate-to-severe impairment (Child-Pugh class B or C): Use of ezetimibe not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zetia&reg;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F169548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. May be taken at the same time as HMG-CoA reductase inhibitors. Administer &ge;2 hours before or &ge;4 hours after bile acid sequestrants.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F169546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in combination with dietary therapy for the treatment of primary hypercholesterolemia (as monotherapy or in combination with HMG-CoA reductase inhibitors); homozygous sitosterolemia; homozygous familial hypercholesterolemia (in combination with atorvastatin or simvastatin); mixed hyperlipidemia (in combination with fenofibrate)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F169597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ezetimibe may be confused with ezogabine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zetia&reg; may be confused with Zebeta&reg;, Zestril&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F169587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (with HMG-CoA reductase inhibitors) (&ge;3 x ULN, 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (3%), pain in extremity (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (4%), sinusitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Abdominal pain, anaphylaxis, angioedema, autoimmune hepatitis (Stolk, 2006), cholecystitis, cholelithiasis, cholestatic hepatitis (Stolk, 2006), CPK increased, depression, dizziness, erythema multiforme, headache, hepatitis, hypersensitivity reactions, myalgia, myopathy, nausea, pancreatitis, paresthesia, rash, rhabdomyolysis, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F169551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ezetimibe or any component of the formulation; concomitant use with an HMG-CoA reductase inhibitor in patients with active hepatic disease, unexplained persistent elevations in serum transaminases; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F169535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild hepatic impairment (Child-Pugh class A); not recommended for use with moderate-or-severe hepatic impairment (Child-Pugh classes B and C).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute). If using concurrent simvastatin in patients with moderate-to-severe renal impairment, the manufacturer of ezetimibe recommends that simvastatin doses exceeding 20 mg be used with caution and close monitoring for adverse events (eg, myopathy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fibric acid derivatives (eg, fenofibrate, gemfibrozil): Concurrent use of fibric acid derivatives may increase the risk of cholelithiasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of SLCO1B1",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Ezetimibe. Ezetimibe may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May increase the serum concentration of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5021760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Food: Ezetimibe did not cause meaningful reductions in fat-soluble vitamin concentrations during a 2-week clinical trial. Effects of long-term therapy have not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F169554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy have not been established; use during pregnancy only if the potential benefit to the mother outweighs the possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F169577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F169555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Before initiation of therapy, patients should be placed on a standard cholesterol-lowering diet for 6 weeks and the diet should be continued during drug therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F169553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zetia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (90): $561.08",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F169543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Total cholesterol profile prior to therapy, and when clinically indicated and/or periodically thereafter. When used in combination with fenofibrate, monitor LFTs and signs and symptoms of cholelithiasis.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F169556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ezetib (IN);",
"     </li>",
"     <li>",
"      Ezetrol (AR, AT, AU, BE, BG, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, KP, MX, MY, NL, NO, NZ, PE, PH, PT, RU, SE, SG, TH, TW, VE);",
"     </li>",
"     <li>",
"      Maxetibe (PY);",
"     </li>",
"     <li>",
"      Zemitra (PK);",
"     </li>",
"     <li>",
"      Zetavim (UY);",
"     </li>",
"     <li>",
"      Zetia (BR, CR, DO, GT, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Zient (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F169534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits absorption of cholesterol at the brush border of the small intestine via the sterol transporter, Niemann-Pick C1-Like1 (NPC1L1). This leads to a decreased delivery of cholesterol to the liver, reduction of hepatic cholesterol stores and an increased clearance of cholesterol from the blood; decreases total C, LDL-cholesterol (LDL-C), ApoB, and triglycerides (TG) while increasing HDL-cholesterol (HDL-C).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F169550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;90% to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes glucuronide conjugation in the small intestine and liver; forms metabolite (active); may undergo enterohepatic recycling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 22 hours (ezetimibe and metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 4-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (78%, 69% as ezetimibe); urine (11%, 9% as metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gustavson LE, Schweitzer SM, Burt DA, et al, &ldquo;Evaluation of the Potential for Pharmacokinetic Interaction Between Fenofibrate and Ezetimibe: A Phase I, Open-Label, Multiple-Dose, Three-Period Crossover Study in Healthy Subjects,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2006, 28 (3):373-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4773/abstract-text/16750452/pubmed\" id=\"16750452\" target=\"_blank\">",
"        16750452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson TA, Marman A, McKenney JM, et al, &ldquo;Safety Considerations With Gastrointestinally Active Lipid-Lowering Drugs,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2007, 99(6A):47C-55C.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4773/abstract-text/17368279/pubmed\" id=\"17368279\" target=\"_blank\">",
"        17368279",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mauro VF and Tuckerman CE, &ldquo;Ezetimibe for Management of Hypercholesterolemia,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(6):839-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4773/abstract-text/12773075/pubmed\" id=\"12773075\" target=\"_blank\">",
"        12773075",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(11):913-27; published erratum appears in",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(12):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4773/abstract-text/16971976/pubmed\" id=\"16971976\" target=\"_blank\">",
"        16971976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peto R, Emberson J, Landray M, et al, &ldquo;Analysis of Cancer Data From Three Ezetimibe Trials,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(13):1357-66. Available at  file://content.nejm.org/cgi/content/full/NEJMsa0806603",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4773/abstract-text/18765432/pubmed\" id=\"18765432\" target=\"_blank\">",
"        18765432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossebo AB, Pederson TR, Boman K, et al, &ldquo;Intensive Lipid Lowering With Simvastatin and Ezetimibe in Aortic Stenosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(13):1343-56.  Available at  file://content.nejm.org/cgi/content/full/NEJMoa0804602",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4773/abstract-text/18765433 /pubmed\" id=\"18765433 \" target=\"_blank\">",
"        18765433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4773/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stolk MF, Becx MC, Kuypers KC, et al, &ldquo;Severe Hepatic Side Effects of Ezetimibe,&rdquo;",
"      <i>",
"       Clin Gastroenterol Hepatol",
"      </i>",
"      , 2006, 4(7):908-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4773/abstract-text/16797241/pubmed\" id=\"16797241\" target=\"_blank\">",
"        16797241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Three New Drugs for Hyperlipidemia,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2003, 45(1151):17-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4773/abstract-text/12612501/pubmed\" id=\"12612501\" target=\"_blank\">",
"        12612501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Bergmann K, Salen G, Lutjohann D, et al, &ldquo;Ezetimibe Effectively Reduces Serum Plant Sterols in Patients With Sitosterolemia (abstract).&rdquo; 73rd European Atherosclerosis Society Congress, 2002. Available at  file://www.kenes.com/73eas/program/abstracts/405.doc",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8790 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4773=[""].join("\n");
var outline_f4_42_4773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169566\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169567\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169589\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169570\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169583\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169571\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169572\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169573\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169545\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169532\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169548\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169546\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169597\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169587\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169551\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169535\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837686\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169539\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5021760\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169541\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169554\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169577\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169555\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169553\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169543\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169556\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169534\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169550\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8790\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8790|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/57/19348?source=related_link\">",
"      Ezetimibe: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17844?source=related_link\">",
"      Ezetimibe: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_42_4774="Management of intergluteal pilonidal disease";
var content_f4_42_4774=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of intergluteal pilonidal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/42/4774/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/42/4774/contributors\">",
"     Daniel J Sullivan, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/42/4774/contributors\">",
"     David C Brooks, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/42/4774/contributors\">",
"     Elizabeth Breen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/42/4774/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/42/4774/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/42/4774/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/42/4774/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/42/4774/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intergluteal pilonidal disease is an infection of the skin and subcutaneous tissue at or near the upper part of the natal cleft of the buttocks (",
"    <a class=\"graphic graphic_figure graphicRef87075 \" href=\"UTD.htm?9/51/10047\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/1\">",
"     1",
"    </a>",
"    ]. Management is variable and guided by the clinical presentation and extensiveness of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The clinical manifestations and diagnosis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24405?source=see_link\">",
"     \"Intergluteal pilonidal disease: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3396938\">",
"    <span class=\"h1\">",
"     ACUTE ABSCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute pilonidal abscess is managed with an incision and drainage (I&amp;D) procedure at the time of presentation, usually under local anesthesia. This management approach is consistent with that described for a skin and subcutaneous abscess at other sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=see_link&amp;anchor=H9#H9\">",
"     \"Skin abscesses, furuncles, and carbuncles\", section on 'Incision and drainage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incision is generally performed lateral to the midline, and all visible hair within the sinus is debrided [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ]. Wounds are packed with gauze, and healing occurs by secondary intention in the acute setting. Curettage of the pilonidal sinus and tract at time of I&amp;D or excision of midline pores is not typically performed in the clinical setting of an acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/4\">",
"     4",
"    </a>",
"    ]. The approach to an I&amp;D procedure is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5865?source=see_link\">",
"     \"Technique of incision and drainage for skin abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An I&amp;D, however, is not the definitive procedure for pilonidal disease, as recurrence rates range from approximately 20 to 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. In a retrospective review of 73 consecutive patients with a first episode of acute pilonidal abscess treated by I&amp;D, 42 (58 percent) healed primarily, with a median time to healing of five weeks; 9 of the 42 developed recurrence of pilonidal disease at a median follow-up of 60 months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/6\">",
"     6",
"    </a>",
"    ]. The overall cure rate following I&amp;D was 45 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1359275\">",
"    <span class=\"h1\">",
"     CHRONIC OR RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive treatment of chronic or persistent pilonidal disease is a surgical excision of all sinus tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/1\">",
"     1",
"    </a>",
"    ]. The surgical procedures range from simple excision with or without primary closure to complex flap reconstruction.",
"   </p>",
"   <p>",
"    Wound management, either primary closure, marsupialization of the wound (edges of the wound are sutured to the underlying fascia, resulting in a smaller wound), or open (delayed closure), is determined by extensiveness of the resection,",
"    <span class=\"nowrap\">",
"     presence/absence",
"    </span>",
"    of infection, and surgeon",
"    <span class=\"nowrap\">",
"     experience/preference.",
"    </span>",
"    However, no single operative intervention is superior to another based upon overall rate of healing, time away from work, and risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/4,7,8\">",
"     4,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1360105\">",
"    <span class=\"h2\">",
"     Surgical approaches",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1360928\">",
"    <span class=\"h3\">",
"     Excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of operative management for chronic or persistent disease is excision of all pilonidal sinus tracts. En bloc excision of the entire pilonidal sinus and epithelialized tracts down to the level of the sacrococcygeal fascia is performed, sparing normal tissue as much as possible (",
"    <a class=\"graphic graphic_figure graphicRef87170 \" href=\"UTD.htm?34/39/35455\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/1,4,9,10\">",
"     1,4,9,10",
"    </a>",
"    ]. The value of using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    to identify associated sinus tracts is debatable [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1361284\">",
"    <span class=\"h3\">",
"     Wound closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal closure of the wound following an excision is debated. Primary closure can be accomplished by either midline (",
"    <a class=\"graphic graphic_figure graphicRef87171 \" href=\"UTD.htm?27/25/28061\">",
"     figure 3",
"    </a>",
"    ) or off-midline techniques (",
"    <a class=\"graphic graphic_figure graphicRef87218 \" href=\"UTD.htm?27/40/28301\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/8,11\">",
"     8,11",
"    </a>",
"    ], including Z-plasty (",
"    <a class=\"graphic graphic_figure graphicRef61176 \" href=\"UTD.htm?4/14/4335\">",
"     figure 5",
"    </a>",
"    ), V-Y advancement flap (",
"    <a class=\"graphic graphic_figure graphicRef65751 \" href=\"UTD.htm?14/3/14399\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/12\">",
"     12",
"    </a>",
"    ], and rhomboid (Limberg) flap (",
"    <a class=\"graphic graphic_figure graphicRef87175 \" href=\"UTD.htm?5/35/5695\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/13\">",
"     13",
"    </a>",
"    ]. The more complex reconstructive operations using flaps are typically reserved for patients with extensive disease or those who have failed simpler operations (eg, excision and sutured midline closure) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/14\">",
"     14",
"    </a>",
"    ]. These reconstructive options allow for excision of greater amounts of involved tissue and are associated with a decrease in tension in the healing wound. In addition, these techniques facilitate wound closure lateral to the natal cleft, an area characteristically moist, hypoxic, and bacteria laden [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12521?source=see_link&amp;anchor=H713392070#H713392070\">",
"     \"Principles of grafts and flaps for reconstructive surgery\", section on 'Flaps'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=see_link\">",
"     \"Z-plasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed closure approaches include leaving the wound open or marsupialization of the skin edges to the sacrococcygeal fascia (",
"    <a class=\"graphic graphic_figure graphicRef87172 \" href=\"UTD.htm?37/58/38829\">",
"     figure 8",
"    </a>",
"    ). The wounds are treated by dressing changes with gauze until healed by secondary intention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H456663840#H456663840\">",
"     \"Basic principles of wound management\", section on 'Wound packing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9600273\">",
"    <span class=\"h4\">",
"     Primary versus delayed closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A primary closure is associated with faster wound healing (complete epithelialization) and a sooner return to work, but a delayed (open) closure is associated with a lower likelihood of pilonidal disease recurrence, as illustrated by the findings from a meta-analysis of 26 randomized trials including 2530 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/8\">",
"     8",
"    </a>",
"    ]. The pertinent results include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Time to wound healing",
"      </strong>",
"      &mdash; Thirteen trials (n = 1421 patients) included data for time to wound healing, but data were not aggregated due to high statistical heterogeneity. Nine trials reported faster",
"      <span class=\"nowrap\">",
"       mean/median",
"      </span>",
"      time to wound healing with a primary closure, and four studies reported similar results without reporting statistical tests. The largest study included 380 patients and found that patients undergoing a primary repair had a significantly faster rate of wound healing compared with patients with open wounds (14.5 versus 60.4 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Time to return to work",
"      </strong>",
"      &mdash; Eleven trials (n = 1729 patients) included data for time to return to work, but data were not aggregated due to high statistical heterogeneity. Nine studies reported faster time to return to work following a primary closure. The largest study included 144 patients and found that patients undergoing a primary repair had a significantly faster rate of return to work compared with patients with open wounds (11.9 versus 17.5 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The remaining two studies utilized marsupialization as the technique for delayed wound closure; patients undergoing primary closure returned to work later than patients treated with the marsupialization (21 versus 3 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/7\">",
"     7",
"    </a>",
"    ] and (17.9 versus 11.2 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Recurrence rate",
"      </strong>",
"      &mdash; Based upon 16 trials that included 1666 patients, the overall recurrence rate of pilonidal disease was 6.9 percent. Primary wound closure was associated with a significantly higher recurrence rate compared with a delayed wound closure (8.7 versus 5.3 percent, relative risk [RR] 1.5, 95% CI 1.08-2.17).",
"     </li>",
"     <li>",
"      <strong>",
"       Rate of surgical site infections",
"      </strong>",
"      &mdash; Overall, surgical site infections (SSI) were low in most trials. Based upon 10 trials that included 1231 patients, there was no significant difference between primary and delayed closure and risk of SSI (8 versus 10 percent, RR 0.76, 0.54-1.08).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9600288\">",
"    <span class=\"h4\">",
"     Off-midline versus midline primary sutured closures",
"    </span>",
"    &nbsp;&mdash;&nbsp;For wounds undergoing a primary closure, an off-midline (lateral) incision is the optimal approach following an excision of pilonidal disease (",
"    <a class=\"graphic graphic_figure graphicRef87218 \" href=\"UTD.htm?27/40/28301\">",
"     figure 4",
"    </a>",
"    ). The meta-analysis discussed above also included the following findings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sutured off-midline wounds took significantly less time to heal compared with sutured midline wounds (n = 100 patients, mean difference 5.4 days, 95% CI 2.3-8.5 days).",
"     </li>",
"     <li>",
"      The risk of SSI was significantly lower for sutured off-midline wounds (n = 541 patients, RR 0.27, 0.13-0.54).",
"     </li>",
"     <li>",
"      The risk of pilonidal disease recurrence was significantly lower for sutured off-midline wounds (n = 574 patients, RR 0.22, 0.11-0.43).",
"     </li>",
"     <li>",
"      The overall complication rate was significantly lower for sutured off-midline wounds (n = 461, RR 0.23, 0.08-0.66).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3396946\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC INCIDENTAL SINUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon limited retrospective data, a surgical excision is not typically performed for patients with an incidental finding of a noninfected pilonidal sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/5,21\">",
"     5,21",
"    </a>",
"    ]. In a retrospective review of 26 patients with an incidental pilonidal sinus undergoing an excision and primary closure, the rate of healing following excision and primary closure was 62 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/21\">",
"     21",
"    </a>",
"    ]. Nonoperative strategies including hygiene, hair control, and observation for signs of an infection, such as acute pain and drainage, are optimal in this clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/4,21\">",
"     4,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9599352\">",
"    <span class=\"h1\">",
"     ROLE OF ANTIBIOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antibiotics is generally limited to the clinical setting of cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/1\">",
"     1",
"    </a>",
"    ]. The most common organisms isolated in chronic pilonidal disease are aerobes, whereas anaerobes such as bacteroides predominate in abscesses. A reasonable antibiotic choice would be a first generation cephalosporin (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef64128 \" href=\"UTD.htm?23/12/23756\">",
"     table 1",
"    </a>",
"    ). The management of cellulitis is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link&amp;anchor=H8#H8\">",
"     \"Cellulitis and erysipelas\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no definitive data to support antibiotic therapy in the management of the patient with an acute abscess or chronic pilonidal disease without cellulitis. A systemic review that included 25 randomized trials found a small postoperative healing benefit when perioperative antibiotics were given, but the magnitude of the benefit was modest, the sample sizes were small, and many studies had methodologic limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, patients with underlying immunosuppression, high risk for endocarditis, methicillin-resistant Staphylococcus aureus (MRSA), or concurrent systemic illness should be considered for ancillary antimicrobial prophylaxis in conjunction with surgical management [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4774/abstract/1\">",
"     1",
"    </a>",
"    ]. Antimicrobial prophylaxis in high-risk clinical settings is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=see_link&amp;anchor=H8#H8\">",
"     \"Skin abscesses, furuncles, and carbuncles\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H22969468#H22969468\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Guidelines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/62/16353?source=see_link\">",
"       \"Patient information: Pilonidal cyst (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with an acute pilonidal abscess should be treated with incision and drainage. The wound should be debrided of all visible hair. (See",
"      <a class=\"local\" href=\"#H3396938\">",
"       'Acute abscess'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with chronic or recurrent pilonidal disease, an excision of the pilonidal sinus and all tracts is performed. (See",
"      <a class=\"local\" href=\"#H1359275\">",
"       'Chronic or recurrent disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A primary wound closure is associated with faster wound healing and a sooner return to work; however, a delayed (open) closure is associated with a lower likelihood of pilonidal disease recurrence. (See",
"      <a class=\"local\" href=\"#H1361284\">",
"       'Wound closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing a sutured primary wound closure, we recommend an off-midline (lateral) closure to reduce the risk of surgical site infections and recurrence as well as to reduce the time to healing (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9600288\">",
"       'Off-midline versus midline primary sutured closures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of antibiotics is generally limited to the clinical setting of cellulitis. However, patients with underlying immunosuppression, high risk for endocarditis, methicillin-resistant Staphylococcus aureus (MRSA), or concurrent systemic illness should be considered for ancillary antimicrobial prophylaxis in conjunction with surgical management. (See",
"      <a class=\"local\" href=\"#H9599352\">",
"       'Role of antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/1\">",
"      Khanna A, Rombeau JL. Pilonidal disease. Clin Colon Rectal Surg 2011; 24:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/2\">",
"      McCallum IJ, King PM, Bruce J. Healing by primary closure versus open healing after surgery for pilonidal sinus: systematic review and meta-analysis. BMJ 2008; 336:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/3\">",
"      Velasco AL, Dunlap WW. Pilonidal disease and hidradenitis. Surg Clin North Am 2009; 89:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/4\">",
"      Humphries AE, Duncan JE. Evaluation and management of pilonidal disease. Surg Clin North Am 2010; 90:113.",
"     </a>",
"    </li>",
"    <li>",
"     Davis BR. Pruritis ani, pilonidal sinus and hidradenitis suppurativa. www.fascrs.org/physicians/education/core_subjects/2010/Pruritus (Accessed on November 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/6\">",
"      Jensen SL, Harling H. Prognosis after simple incision and drainage for a first-episode acute pilonidal abscess. Br J Surg 1988; 75:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/7\">",
"      Gencosmanoglu R, Inceoglu R. Modified lay-open (incision, curettage, partial lateral wall excision and marsupialization) versus total excision with primary closure in the treatment of chronic sacrococcygeal pilonidal sinus: a prospective, randomized clinical trial with a complete two-year follow-up. Int J Colorectal Dis 2005; 20:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/8\">",
"      Al-Khamis A, McCallum I, King PM, Bruce J. Healing by primary versus secondary intention after surgical treatment for pilonidal sinus. Cochrane Database Syst Rev 2010; :CD006213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/9\">",
"      Oncel M, Kurt N, Kement M, et al. Excision and marsupialization versus sinus excision for the treatment of limited chronic pilonidal disease: a prospective, randomized trial. Tech Coloproctol 2002; 6:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/10\">",
"      Bascom J. Pilonidal disease: long-term results of follicle removal. Dis Colon Rectum 1983; 26:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/11\">",
"      Petersen S, Koch R, Stelzner S, et al. Primary closure techniques in chronic pilonidal sinus: a survey of the results of different surgical approaches. Dis Colon Rectum 2002; 45:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/12\">",
"      Nursal TZ, Ezer A, Calikan K, et al. Prospective randomized controlled trial comparing V-Y advancement flap with primary suture methods in pilonidal disease. Am J Surg 2010; 199:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/13\">",
"      Faux W, Pillai SC, Gold DM. Limberg flap for pilonidal disease: the \"no-protractor\" approach, 3 steps to success. Tech Coloproctol 2005; 9:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/14\">",
"      Hull TL, Wu J. Pilonidal disease. Surg Clin North Am 2002; 82:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/15\">",
"      Bascom J, Bascom T. Failed pilonidal surgery: new paradigm and new operation leading to cures. Arch Surg 2002; 137:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/16\">",
"      Bascom J, Bascom T. Utility of the cleft lift procedure in refractory pilonidal disease. Am J Surg 2007; 193:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/17\">",
"      Tezel E. Cleft lift procedure with excision of pits for extensive sacrococcygeal pilonidal disease. Colorectal Dis 2006; 8:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/18\">",
"      Al-Salamah SM, Hussain MI, Mirza SM. Excision with or without primary closure for pilonidal sinus disease. J Pak Med Assoc 2007; 57:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/19\">",
"      Fazeli MS, Adel MG, Lebaschi AH. Comparison of outcomes in Z-plasty and delayed healing by secondary intention of the wound after excision of the sacral pilonidal sinus: results of a randomized, clinical trial. Dis Colon Rectum 2006; 49:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/20\">",
"      Karakayali F, Karagulle E, Karabulut Z, et al. Unroofing and marsupialization vs. rhomboid excision and Limberg flap in pilonidal disease: a prospective, randomized, clinical trial. Dis Colon Rectum 2009; 52:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/21\">",
"      Doll D, Friederichs J, Boulesteix AL, et al. Surgery for asymptomatic pilonidal sinus disease. Int J Colorectal Dis 2008; 23:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4774/abstract/22\">",
"      O'Meara SM, Cullum NA, Majid M, Sheldon TA. Systematic review of antimicrobial agents used for chronic wounds. Br J Surg 2001; 88:4.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7604 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4774=[""].join("\n");
var outline_f4_42_4774=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3396938\">",
"      ACUTE ABSCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1359275\">",
"      CHRONIC OR RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1360105\">",
"      Surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1360928\">",
"      - Excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1361284\">",
"      - Wound closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9600273\">",
"      Primary versus delayed closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9600288\">",
"      Off-midline versus midline primary sutured closures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3396946\">",
"      ASYMPTOMATIC INCIDENTAL SINUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9599352\">",
"      ROLE OF ANTIBIOTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/7604\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/7604|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/51/10047\" title=\"figure 1\">",
"      Pilonidal sinus and tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/39/35455\" title=\"figure 2\">",
"      Excision of pilonidal tract and sinus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/25/28061\" title=\"figure 3\">",
"      Primary closure of excised pilonidal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/40/28301\" title=\"figure 4\">",
"      Primary closure off-midline for intergluteral pilonidal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/14/4335\" title=\"figure 5\">",
"      Classic z-plasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/3/14399\" title=\"figure 6\">",
"      V Y advancement flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/35/5695\" title=\"figure 7\">",
"      Rhomboid flap closure for pilonidal disease excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/58/38829\" title=\"figure 8\">",
"      Marsupialized pilonidal wound closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/7604|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/12/23756\" title=\"table 1\">",
"      Empiric antibiotics cellulitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24405?source=related_link\">",
"      Intergluteal pilonidal disease: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/62/16353?source=related_link\">",
"      Patient information: Pilonidal cyst (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12521?source=related_link\">",
"      Principles of grafts and flaps for reconstructive surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=related_link\">",
"      Skin abscesses, furuncles, and carbuncles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5865?source=related_link\">",
"      Technique of incision and drainage for skin abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=related_link\">",
"      Z-plasty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_42_4775="Bromocriptine: Pediatric drug information";
var content_f4_42_4775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bromocriptine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"    see \"Bromocriptine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/23/35189?source=see_link\">",
"    see \"Bromocriptine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cycloset&reg;;",
"     </li>",
"     <li>",
"      Parlodel&reg;;",
"     </li>",
"     <li>",
"      Parlodel&reg; SnapTabs&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Bromocriptine;",
"     </li>",
"     <li>",
"      PMS-Bromocriptine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1001926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-Parkinson's Agent, Dopamine Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Dopamine Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ergot Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1001955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"      see \"Bromocriptine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"     <b>",
"      Hyperprolactinemia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents 11-15 years (based on limited information): Oral: Initial: 1.25-2.5 mg daily; dosage may be increased as tolerated to achieve a therapeutic response; usual dosage range: 2.5-10 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents &ge;16 years: Oral: Initial: 1.25-2.5 mg daily; may be increased by 2.5 mg/day as tolerated every 2-7 days until optimal response; usual dosage range: 2.5-15 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acromegaly:",
"     </b>",
"     Oral: Initial: 1.25-2.5 mg daily increasing by 1.25-2.5 mg daily as necessary every 3-7 days; usual dose: 20-30 mg/day (maximum: 100 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hyperprolactinemia:",
"     </b>",
"     Oral: Initial: 1.25-2.5 mg daily; may be increased by 2.5 mg daily as tolerated every 2-7 days until optimal response; usual dosage range: 2.5-15 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Neuroleptic malignant syndrome (NMS):",
"     </b>",
"     Oral: 2.5 mg (orally or via gastric tube) every 8-12 hours, increased to a maximum of 45 mg daily, if needed; continue therapy until NMS is controlled, then taper slowly (Gortney, 2009; Strawn, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Parkinsonism:",
"     </b>",
"     Oral: 1.25 mg twice daily, increased by 2.5 mg/day in 2- to 4-week intervals as needed (maximum daily dose: 100 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 2 diabetes mellitus (Cycloset&reg;):",
"     </b>",
"     Oral: Initial: 0.8 mg once daily; may increase at weekly intervals in 0.8 mg increments as tolerated; usual dose: 1.6-4.8 mg daily (maximum: 4.8 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     No guidelines are available; however, may be necessary due to extensive metabolism",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parlodel&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cycloset&reg;: 0.8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parlodel&reg; SnapTabs&reg;: 2.5 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes Cycloset&reg;",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4597934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be taken with food to decrease GI distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cycloset&reg;: Administer within 2 hours of waking in the morning",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13892658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at or below 25&deg;C (77&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1001927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of dysfunctions associated with hyperprolactinemia, including amenorrhea with or without galactorrhea, infertility, or hypogonadism (FDA approved in adults); treatment of prolactin-secreting adenomas (FDA approved in ages &ge;11 years and adults); treatment of acromegaly (FDA approved in adults); treatment of Parkinson's disease (FDA approved in adults); treatment of type 2 diabetes mellitus as an adjunct to diet and exercise (Cycloset&reg;: FDA approved in adults); has also been used for neuroleptic malignant syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F142623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bromocriptine may be confused with benztropine, brimonidine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cycloset&reg; may be confused with Glyset&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Parlodel&reg; may be confused with pindolol, Provera&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F142621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension (including postural/orthostatic), Raynaud's syndrome exacerbation, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, fatigue, headache, lightheadedness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, dyspepsia, GI bleeding, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Digital vasospasm, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection, flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, blindness (transient), bradycardia, cardiac valve fibrosis, cerebrospinal fluid rhinorrhea, confusion, constrictive pericarditis, depression, dysphagia, epileptiform seizure, ergotism, erythromelalgia, gastrointestinal ulceration, hallucinations, hypertension (postpartum), insomnia, MI (postpartum), pericardial effusion, peripheral edema, pleural effusion, pleural/pulmonary fibrosis, pleurisy, psychomotor agitation/excitation, psychosis, retroperitoneal fibrosis, seizures (postpartum), status epilepticus (postpartum), stroke (postpartum), sudden onset of sleep, tachycardia, urinary incontinence, urinary retention, ventricular tachycardia, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Withdrawal reactions: Abrupt discontinuation has resulted in rare cases of a withdrawal reaction with symptoms similar to neuroleptic malignant syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reported with dopamine agonists: Impulsive/compulsive behaviors (eg, pathological gambling, hypersexuality, binge eating)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1001931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bromocriptine, ergot alkaloids, or any component",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parlodel&reg;: Uncontrolled hypertension; pregnancy (risk:benefit evaluation must be performed in women who become pregnant during treatment for acromegaly, prolactinoma, or Parkinson's disease; hypertension during treatment should generally result in efforts to withdraw therapy); postpartum women with a history of coronary artery disease or other severe cardiovascular conditions (unless withdrawal of medication is medically contraindicated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cycloset&reg;: Syncopal migraine; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4597932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiovascular disease (myocardial infarction, arrhythmia), peptic ulcer, dementia, hepatic and/or renal impairment, and psychosis. Not recommended for use to control or prevent lactation or in patients with uncontrolled hypertension. Concurrent antihypertensives or drugs which may alter blood pressure should be used with caution. Avoid use in patients with rare hereditary galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1001932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Complete evaluation of pituitary function should be completed prior to initiation of treatment for any hyperprolactinemia-associated dysfunction. Patients not seeking pregnancy or those with large adenomas should be advised to use contraception other than oral contraceptives during treatment with bromocriptine. Pregnancy testing is recommended at least every 4 weeks during the amenorrheic period and, once menses are reinitiated, every time a patient misses a menstrual period.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Symptomatic hypotension may occur in a significant number of patients (up to 30%) especially during the first days of treatment. Ergot alkaloids and derivatives have been associated with fibrotic valve thickening (eg, aortic, mitral, tricuspid) and is usually associated with long-term, chronic use. Hypertension, seizures, MI, and stroke have been rarely associated with therapy. Severe headache or visual changes may precede events. The onset of reactions may be immediate or delayed (often may occur in the second week of therapy). Patients who receive bromocriptine during and immediately following pregnancy as a continuation of previous therapy (eg, acromegaly) should be closely monitored for cardiovascular effects. Prolactin-secreting adenomas may expand and compress the optic or other cranial nerves. Monitoring and careful evaluation of visual changes during the treatment of hyperprolactinemia is recommended to differentiate between tumor shrinkage and traction on the optic chiasm. Rapidly progressing visual field loss requires neurosurgical consultation. In most cases, compression resolves following delivery.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Rare cases of pleural and pericardial effusions as well as pleural and pulmonary fibrosis and constrictive pericarditis have been reported, particularly with long term and high-dose treatment. Retroperitoneal fibrosis has also been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In the treatment of acromegaly, discontinuation is recommended if tumor expansion occurs during therapy. Cold sensitive digital vasospasm may occur in some patients with acromegaly and may be reversed with dosage reduction. Discontinuation of therapy in patients with macroadenomas has been associated with rapid regrowth of tumor and increased prolactin serum levels. Patients treated with pituitary radiation should have an annual 4-8 week withdrawal from bromocriptine to assess both the clinical effects of radiation on the disease process as well as the effects of bromocriptine. Recurrence of signs and symptoms or increases in growth hormone indicate the need to resume treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Safety has not been established for therapy duration &gt;2 years in patients with Parkinson's disease. Concurrent use with levodopa has been associated with an increased risk of hallucinations; consider dosage reduction and/or discontinuation in patients with hallucinations. Hallucinations may require weeks to months before resolution. Dopamine agonists used to treat Parkinson's have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions, and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases. Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed. Bromocriptine has been associated with sudden onset of sleep during daily activities, in some cases without awareness or warning signs primarily in patients with Parkinson&rsquo;s disease. A reduction in dosage or termination of therapy may be necessary. Patients must be cautioned about performing tasks which require mental alertness.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In the management of type 2 diabetes mellitus, Cycloset&reg; (\"quick-release\" tablet) should not be interchanged with any other bromocriptine product due to formulation differences and resulting pharmacokinetic profile. Therapy is not appropriate in patients with diabetic ketoacidosis (DKA) or type 1 diabetes mellitus due to lack of efficacy in these patient populations. There is limited efficacy information regarding use in combination with thiazolidinediones or in combination with insulin. Combination therapy with other hypoglycemic agents may increase risk for hypoglycemic events; dose reduction of concomitant hypoglycemics may be warranted. Concomitant use with dopamine receptor antagonists, including neuroleptic agents with dopamine receptor antagonist properties (clozapine, olanzapine, ziprasidone), is not recommended; efficacy may be reduced. Concomitant use of dopamine agonists is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F142610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Bromocriptine. Bromocriptine may enhance the adverse/toxic effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: May enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Atypical): May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Typical): Anti-Parkinson's Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Bromocriptine may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1001946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The herbal medicine St John's wort (",
"     <i>",
"      Hypericum perforatum",
"     </i>",
"     ) may decrease bromocriptine levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F142546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2798907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No evidence of teratogenicity or fetal toxicity in animal studies. Bromocriptine is used for ovulation induction in women with hyperprolactinemia. In general, therapy should be discontinued if pregnancy is confirmed unless needed for treatment of macroprolactinoma. Data collected from women taking bromocriptine during pregnancy suggest the incidence of birth defects is not increased with use. However, the majority of women discontinued use within 8 weeks of pregnancy. Women not seeking pregnancy should be advised to use appropriate contraception.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1001961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure closely as well as hepatic, hematopoietic, and cardiovascular function; visual field monitoring is recommended (prolactinoma); pregnancy testing during amenorrheic period; growth hormone and prolactin levels; Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and serum glucose (type 2 diabetes mellitus)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1001947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Semisynthetic ergot alkaloid derivative and a dopamine receptor agonist which activates postsynaptic dopamine receptors in the tuberoinfundibular process which results in inhibition of pituitary prolactin secretion. Stimulation of dopamine receptors in the corpus striatum is beneficial in the treatment of Parkinson&rsquo;s disease, a condition characterized by a progressive deficiency in dopamine synthesis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In the treatment of type 2 diabetes mellitus, the mechanism of action is unknown; however, bromocriptine is believed to affect circadian rhythms which are mediated, in part, by dopaminergic activity, and are believed to play a role in obesity and insulin resistance. It is postulated that bromocriptine (when administered during the morning and released into the systemic circulation in a rapid, \"pulse-like\" dose) may reset hypothalamic circadian activities which have been altered by obesity, thereby resulting in the reversal of insulin resistance and decreases in glucose production, without increasing serum insulin concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F4597933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of prolactin concentrations (Parlodel&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 5-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 8-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1001949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Parlodel&reg;: 28%; Cycloset&reg;: 65% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~61L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90% to 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic via CYP3A4; extensive first-pass biotransformation (93%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Parlodel&reg;: Biphasic with terminal half-life: 15 hours; range: 8-20 hours; Cycloset&reg;: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parlodel&reg;: 2.5 &plusmn; 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cycloset&reg;: 53 minutes (fasted); 90-120 minutes (high-fat meal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces; urine (2% to 6% as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1001964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/23/35189?source=see_link\">",
"      see \"Bromocriptine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take exactly as directed (may be prescribed in conjunction with levodopa/carbidopa); do not change dosage or discontinue this medicine without consulting prescriber. Therapeutic effects may take several weeks or months to achieve and you may need frequent monitoring during first weeks of therapy. Take with meals if GI upset occurs, before meals if dry mouth occurs, or after eating if drooling or if nausea occurs. Take at the same time each day; if using for diabetes, take within 2 hours of waking in the morning with food. Maintain adequate hydration unless instructed to restrict fluid intake; void before taking medication. Do not use alcohol, prescription or OTC sedatives, or CNS depressants without consulting prescriber. Urine or perspiration may appear darker. May cause drowsiness, dizziness, confusion, or vision changes (use caution when driving, climbing stairs, or engaging in tasks requiring alertness until response to drug is known); orthostatic hypotension (use caution when rising from sitting or lying position); constipation (increased exercise, fluids, fruit, or fiber may help); nasal congestion (consult prescriber for appropriate relief); or nausea, vomiting, loss of appetite, or stomach discomfort (small frequent meals, frequent mouth care, chewing gum, or sucking lozenges may help). Report unresolved constipation or vomiting; chest pain or irregular heartbeat; acute headache or dizziness; CNS changes (eg, hallucination, loss of memory, seizures, acute headache, nervousness); painful or difficult urination; increased muscle spasticity, rigidity, or involuntary movements; skin rash; or significant worsening of condition.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1001966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usually used with levodopa or levodopa/carbidopa to treat Parkinson's disease. When adding bromocriptine, the dose of levodopa/carbidopa can usually be decreased.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      de Groot AN, van Dongen PW, Vree TB, et al, &ldquo;Ergot Alkaloids. Current Status and Review of Clinical Pharmacology and Therapeutic Use Compared With Other Oxytocics in Obstetrics and Gynaecology,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 56(4):523-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4775/abstract-text/9806101/pubmed\" id=\"9806101\" target=\"_blank\">",
"        9806101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gillam MP, Fideleff H, Boquete HR, et al, &ldquo;Prolactin Excess: Treatment and Toxicity,&rdquo;",
"      <i>",
"       Pediatr Endocrinol Rev",
"      </i>",
"      , 2004, 2(suppl)1:108-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4775/abstract-text/16456489/pubmed\" id=\"16456489\" target=\"_blank\">",
"        16456489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gortney JS, Fagan A, and Kissack JC, \"Neuroleptic Malignant Syndrome Secondary to Quetiapine,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2009, 43(4):785-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4775/abstract-text/19299325/pubmed\" id=\"19299325\" target=\"_blank\">",
"        19299325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lejoyeux M, et al, &ldquo;Serotonin Syndrome: Incidence, Symptoms, and Treatment,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 1994, 2:132-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Melmed S and Braunstein GD, &ldquo;Bromocriptine and Pleuropulmonary Disease,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1989, 149(2):258-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4775/abstract-text/2916870/pubmed\" id=\"2916870\" target=\"_blank\">",
"        2916870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molitch ME, &ldquo;Management of Prolactinomas During Pregnancy,&rdquo;",
"      <i>",
"       J Reprod Med",
"      </i>",
"      , 1999, 44(12 Suppl):1121-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4775/abstract-text/10649822/pubmed\" id=\"10649822\" target=\"_blank\">",
"        10649822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgans D, &ldquo;Re: Parlodel,&rdquo;",
"      <i>",
"       Aust N Z J Obstet Gynaecol",
"      </i>",
"      , 1995, 35(2):228-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4775/abstract-text/7677704/pubmed\" id=\"7677704\" target=\"_blank\">",
"        7677704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mueller PS, Vester JW, and Fermaglich J, &ldquo;Neuroleptic Malignant Syndrome. Successful Treatment With Bromocriptine,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1983, 249(3):386-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4775/abstract-text/6129331/pubmed\" id=\"6129331\" target=\"_blank\">",
"        6129331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parkes D, &ldquo;Drug Therapy: Bromocriptine,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1979, 301(16):873-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4775/abstract-text/384250/pubmed\" id=\"384250\" target=\"_blank\">",
"        384250",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strawn JR, Keck PE Jr, and Caroff SN, \"Neuroleptic Malignant Syndrome,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(6):870-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4775/abstract-text/17541044/pubmed\" id=\"17541044\" target=\"_blank\">",
"        17541044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13022 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4775=[""].join("\n");
var outline_f4_42_4775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142570\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142571\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1001926\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1001955\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142550\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142536\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4597934\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13892658\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1001927\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142623\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142621\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1001931\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4597932\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1001932\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142610\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142545\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1001946\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142546\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2798907\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1001961\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1001947\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4597933\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1001949\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1001964\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1001966\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13022\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13022|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=related_link\">",
"      Bromocriptine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/23/35189?source=related_link\">",
"      Bromocriptine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_42_4776="Acute bacterial prostatitis";
var content_f4_42_4776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute bacterial prostatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/42/4776/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/42/4776/contributors\">",
"     Alain Meyrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/42/4776/contributors\">",
"     Thomas Fekete, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/42/4776/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/42/4776/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/42/4776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/42/4776/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/42/4776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prostate is subject to various inflammatory disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/1\">",
"     1",
"    </a>",
"    ]. One of these syndromes is acute bacterial prostatitis, an acute infection of the prostate, usually caused by Gram-negative organisms. The clinical presentation is generally well defined, and antimicrobial therapy remains the mainstay of treatment.",
"   </p>",
"   <p>",
"    Acute bacterial prostatitis will be reviewed here. Chronic bacterial prostatitis and chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=see_link\">",
"     \"Chronic bacterial prostatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=see_link\">",
"     \"Chronic prostatitis/chronic pelvic pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of dysuria in men, including cystitis, urethritis, and epididymitis, are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15479?source=see_link\">",
"     \"Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44360?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of the acute scrotum in adults\", section on 'Epididymitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29437530\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Entry of microorganisms into the prostate gland almost always occurs via the urethra. In most cases, bacteria migrate from the urethra or bladder through the prostatic ducts, with intraprostatic reflux of urine (",
"    <a class=\"graphic graphic_figure graphicRef54803 \" href=\"UTD.htm?19/35/20023\">",
"     figure 1",
"    </a>",
"    ). As a result, there may be concomitant infection in the bladder or epididymis. Uropathogenic bacterial isolates that cause prostatitis may have a higher accumulation of specialized virulence factors than those involved in cystitis alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13503206\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, prostatitis syndromes are a very common presentation in the clinical setting and tend to occur in young and middle-aged men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/4\">",
"     4",
"    </a>",
"    ]. However, acute bacterial prostatitis accounts for a minority of these cases.",
"   </p>",
"   <p>",
"    In a study of 58,955 ambulatory visits to clinicians by men over the age of 18 years reported to the United States National Ambulatory Medical Care Surveys from 1990 to 1994, 5 percent listed genitourinary tract symptoms as one of the reasons for the visit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/5\">",
"     5",
"    </a>",
"    ]. Prostatitis was listed as a diagnosis in an estimated two million visits annually. Acute bacterial prostatitis, however, accounted for only 4 percent of prostatitis diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29437419\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute prostatitis can occur in the setting of cystitis, urethritis, or other urogenital tract infections. Thus, underlying conditions such as functional or anatomical anomalies (eg, urethral strictures), that predispose to other urogenital infections can increase the risk of prostatitis. Prostate infections following urogenital instrumentation, including chronic indwelling bladder catheterization, intermittent bladder catheterization, and prostate biopsy are well documented [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. As an example, in a retrospective study of 1339 men who underwent transrectal ultrasound-guided prostate biopsy, 28 men (2.1 percent) developed acute prostatitis a mean of three days post-biopsy, despite receiving peri-procedural fluoroquinolone prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lower urinary tract symptoms, including those caused by bacterial prostatitis, also occur more frequently in patients with HIV infection than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Why this occurs is not clear. While immunosuppression associated with HIV certainly increases the risk of prostatitis, HIV-infected men without AIDS-defining illnesses or low CD4 cell counts also report lower urinary tract symptoms more frequently than uninfected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients with acute bacterial prostatitis have no clear risk factors. Anecdotally, trauma (eg, bicycle or horseback riding), dehydration, and sexual abstinence have been thought to predispose to prostatitis. However, these factors have not been established by well-controlled studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogens associated with acute prostatitis reflect the spectrum of organisms causing cystitis, urethritis, and deeper genital tract infections (such as epididymitis). Thus, gram-negative infections, especially with Enterobacteriaceae (typically Escherichia coli or Proteus species), are the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/11\">",
"     11",
"    </a>",
"    ]. As examples, in retrospective studies of men with acute bacterial prostatitis, such pathogens have been identified in positive urine cultures at the following frequencies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      E. coli &ndash; 58 to 88 percent",
"     </li>",
"     <li>",
"      Proteus species &ndash; 3 to 6 percent",
"     </li>",
"     <li>",
"      Other Enterobacteriaceae (Klebsiella, Enterobacter, and Serratia species) &ndash; 3 to 11 percent",
"     </li>",
"     <li>",
"      Pseudomonas aeruginosa &ndash; 3 to 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certain gram-positive cocci (including Staphylococcus aureus, streptococci, and enterococci) have also been implicated in acute bacterial prostatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/12,13,15\">",
"     12,13,15",
"    </a>",
"    ]. Acute staphylococcal prostatitis, in particular, may result from bacteremia that accompanies a remote S. aureus infection elsewhere. Isolation of S. aureus from prostatic secretions should trigger an evaluation for a remote or endovascular staphylococcal infection.",
"   </p>",
"   <p>",
"    Instrumentation of the prostate has been associated with subsequent acute bacterial prostatitis due to organisms with broad resistance to antibiotics, including fluoroquinolone-resistant E. coli and Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. This is likely related to the use of peri-procedural prophylactic fluoroquinolones.",
"   </p>",
"   <p>",
"    Sexually active men may have sexually transmitted urogenital infections, such as urethritis and epididymitis, which also acutely involve the prostate, in which case Neisseria gonorrhoeae and Chlamydia trachomatis are important pathogens. This problem tends to occur more often in younger men, but age is not a specific risk factor for these sexually transmitted infections.",
"   </p>",
"   <p>",
"    In HIV-infected patients, the microbiology typically reflects that seen in the general population; however, involvement with other pathogens, including Salmonella typhi and N. gonorrhoeae, has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients or travelers from regions where Burkholderia pseudomallei is endemic (eg, southern and southeast Asia or northern Australia) this uncommon organism has also been described as a cause of acute prostatitis and prostatic abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39577?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of melioidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrent infection after completion of therapy is usually caused by the same organism that was found in the original infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of acute prostatitis is generally not subtle. Patients are typically acutely ill, with spiking fever, chills, malaise, myalgia, dysuria, irritative urinary symptoms (frequency, urgency, urge incontinence), pelvic or perineal pain, and cloudy urine. Men may also complain of pain at the tip of the penis. Swelling of the acutely inflamed prostate can cause voiding symptoms, ranging from dribbling and hesitancy to acute urinary retention. In a retrospective review of 614 cases of men who presented to an emergency department in Spain and were diagnosed with acute bacterial prostatitis, irritative symptoms were observed most commonly (93 percent), with obstructive symptoms (poor stream, hesitancy) and fever reported in 25 and 34 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/12\">",
"     12",
"    </a>",
"    ]. No specific characteristics of urinary symptoms (eg, end-stream dysuria) have been clearly associated with prostatitis.",
"   </p>",
"   <p>",
"    Rarely, patients lack these local symptoms and present instead with constitutional symptoms or a flu-like illness.",
"   </p>",
"   <p>",
"    On exam, the prostate is often warm, firm, edematous, and exquisitely tender. Common laboratory findings include peripheral leukocytosis, pyuria, bacteriuria, and, occasionally, positive blood cultures. Inflammatory markers (erythrocyte sedimentation rate, C-reactive protein) may be elevated. Inflammation of the prostate can also lead to an elevated serum prostate specific antigen (PSA) level [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, if serum PSA testing for prostate cancer screening is planned, it should be deferred for one month following acute prostatitis. A detailed discussion of the risks and benefits of prostate cancer screening is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=see_link\">",
"     \"Measurement of prostate specific antigen\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13503467\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of acute bacterial prostatitis include bacteremia, epididymitis, chronic bacterial prostatitis, prostatic abscesses, and metastatic infection (eg, spinal or sacroiliac infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients with underlying valvular heart disease or a valvular prosthesis may be at risk for endocarditis when prostatitis is caused by certain bacterial pathogens, particularly gram-positive bacteria. These complications are more likely to occur if diagnosis and antimicrobial therapy is delayed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23323139\">",
"    <span class=\"h3\">",
"     Prostatic abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of prostatic abscess is currently low with the use of appropriate antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/21\">",
"     21",
"    </a>",
"    ]. In a prospective study of transrectal ultrasonography of the prostate in 45 men hospitalized for acute bacterial prostatitis, no lesions with sonographic characteristics of prostatic abscesses were identified, despite detection of other, often transient, prostatic lesions in almost half of the men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/22\">",
"     22",
"    </a>",
"    ]. Certain underlying conditions, such as diabetes mellitus or HIV-related immunosuppression, may predispose to the development of prostatic abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signs and symptoms of a prostatic abscess are similar to those of bacterial prostatitis in general, but may persist despite appropriate antibiotic therapy; in addition, fluctuance of the prostate on gentle digital exam can suggest an underlying abscess. On transrectal ultrasound, abscesses appear as hypoechoic or anechoic areas with thick walls or peripheral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Computed tomography (CT) findings include nonenhancing fluid-density collections that can be multiseptated or rim-enhancing lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23323217\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of typical symptoms of prostatitis should prompt digital rectal exam, and the finding of an edematous and tender prostate on physical exam in this setting usually establishes the diagnosis of acute bacterial prostatitis. Digital rectal examination should be performed gently; vigorous prostate massage should be avoided since it is uncomfortable, allows no additional diagnostic or therapeutic benefit, and increases the risk for bacteremia. In patients who present with constitutional symptoms only, establishing a diagnosis of acute prostatitis is challenging. Laboratory findings of leukocytosis, pyuria, bacteriuria, or an elevated serum prostate specific antigen (PSA) level can support the diagnosis, and should prompt consideration of digital rectal exam. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In order to establish the microbial etiology, a urine Gram stain and culture should be obtained in all men suspected of having acute prostatitis. Gram stain of the urine, if positive, can be used as a guide to initial therapy. (See",
"    <a class=\"local\" href=\"#H13503301\">",
"     'Antimicrobial therapy'",
"    </a>",
"    below.) Urine culture typically reveals a causative organism in acute prostatitis, unless antibiotics were recently used.",
"   </p>",
"   <p>",
"    Blood cultures usually are not necessary for microbial diagnosis, and we typically do not perform them for this reason alone. In a retrospective review of 261 men with acute prostatitis in whom urine and blood cultures were collected, blood cultures provided additional microbial information in 14 patients (5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/14\">",
"     14",
"    </a>",
"    ]. However, blood cultures are useful to assess for complications in patients with underlying cardiac valvular disease or clinical evidence of impending or severe sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17630369\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23323238\">",
"    <span class=\"h2\">",
"     Evaluation for complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures to evaluate for bacteremia are warranted in patients with signs suggestive of severe sepsis (eg, hypotension, hematologic derangements). Additionally, a high level of suspicion for bacteremic complications of acute prostatitis is warranted in patients with underlying conditions that may predispose to them (eg, endocarditis in patients with valvular disease or prostheses).",
"   </p>",
"   <p>",
"    In particular, when S. aureus is recovered from a urine culture, it is important to perform blood cultures to be certain the bacteriuria reflects local infection and not seeding of the prostate or urine in the setting of bacteremia, or even underlying endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26649?source=see_link\">",
"     \"Complications of Staphylococcus aureus bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging studies are generally not indicated in acute bacterial prostatitis, unless there is clinical suspicion for a prostatic abscess. In patients who have persistent clinical or laboratory abnormalities despite appropriate antimicrobial therapy, an abscess can be diagnosed radiographically with prostate ultrasonography or computed tomography (CT) scan [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13503467\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17630388\">",
"    <span class=\"h2\">",
"     Evaluation for anatomical abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the acute episode, underlying anatomical abnormalities that may have predisposed to an acute prostatic infection may be sought and, if possible, remedied to decrease the risk of recurrence. Consultation with a urologist for this evaluation may be useful in patients with recurrent infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172458394\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common alternate diagnosis to consider in a man who presents with dysuria, frequency,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urgency, and who has pyuria and bacteriuria, is an isolated lower urinary tract infection (UTI), or cystitis. UTIs in men generally occur in the presence of a predisposing functional or anatomic abnormality, such as prostatic hypertrophy or genitourinary instrumentation, which increases the risk of infection, although they can also uncommonly occur in otherwise healthy men. While isolated UTIs likely involve some amount of bacterial contamination along the prostatic ducts, this prostatic contamination may remain superficial without overt prostatic inflammation or suppuration. In such cases, fever, chills, and constitutional symptoms are generally absent, and there is no prostatic tenderness on digital rectal exam. Men who lack this evidence of clinically significant prostatic involvement can be managed as having acute uncomplicated or complicated cystitis, depending on the presence of predisposing features, but should be monitored for lack of clinical response, which would warrant reevaluation for the possibility of underlying prostatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15479?source=see_link&amp;anchor=H12809190#H12809190\">",
"     \"Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men\", section on 'Cystitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=see_link&amp;anchor=H2922187#H2922187\">",
"     \"Acute complicated cystitis and pyelonephritis\", section on 'Cystitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tenderness of the prostate on exam is also generally not found in other acute causes of dysuria (eg, urethritis, epididymitis) in the absence of coexisting prostatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=see_link\">",
"     \"Infectious causes of dysuria in adult men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with conditions, such as benign prostatic hyperplasia and overactive bladder, may also initially present with lower urinary tract symptoms, but typically do not have fever, pyuria, and other signs or symptoms of infection. These conditions are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23323367\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acute prostatitis includes antimicrobial therapy and supportive measures to reduce symptoms. Rarely, more invasive intervention is indicated to manage complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23323375\">",
"    <span class=\"h2\">",
"     Indications for hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with acute bacterial prostatitis warrant inpatient hospitalization. Patients who have no major comorbidities, no signs or symptoms of severe sepsis, and who can reliably take and tolerate oral antibiotics, can likely be managed appropriately in the outpatient setting. A short hospital stay in patients suspected of having bacteremia, or for monitoring purposes in those patients who would not otherwise be able to promptly return to medical care in the case of decompensation, may be prudent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13503301\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of antimicrobials may be used for the treatment of acute prostatitis, which should be treated empirically pending culture results. Data on the treatment of acute prostatitis are limited, and there are no comparative trials evaluating the optimal antimicrobial choice. Thus, recommendations for empiric therapy are based on the likelihood of the infecting organism. Although not all antibiotics can penetrate into prostatic tissue, the presence of acute inflammation generally allows entry of drugs that would not otherwise achieve therapeutic levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=see_link&amp;anchor=H19592317#H19592317\">",
"     \"Chronic bacterial prostatitis\", section on 'Antimicrobial penetration into prostatic tissue'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empiric antibiotic therapy should adequately treat gram-negative organisms unless a urine Gram stain is available and suggests an alternate bacterial cause. For patients with acute prostatitis who can take oral medications, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (one double-strength tab orally every 12 hours) or a fluoroquinolone (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 mg orally every 12 hours or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    500 mg orally once daily) as empiric therapy. We typically choose one of these antimicrobial agents because they achieve high levels in prostatic tissue. Although this may not be an issue in the acute setting, where prostatic inflammation allows penetration of a broader range of antibiotics, the ability of an antibiotic to penetrate prostate tissue is thought to be important during prolonged therapy, while inflammation is resolving [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/27\">",
"     27",
"    </a>",
"    ]. The choice between these should take into account patient tolerance and regional patterns of Enterobacteriaceae drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link&amp;anchor=H899949163#H899949163\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\", section on 'Antimicrobial resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with acute bacterial prostatitis may need to be hospitalized for parenteral antibiotic therapy if they cannot tolerate oral medication, demonstrate signs of severe sepsis, or have bacteremia. In such cases, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    may be given with or without an aminoglycoside (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily, if the creatinine clearance is normal). An intravenous beta-lactam with activity against Enterobacteriaceae with or without an aminoglycoside is an alternate initial regimen for hospitalized patients. The choice between these should take into account patient tolerance and regional patterns of Enterobacteriaceae drug resistance.",
"   </p>",
"   <p>",
"    Empiric treatment with an intravenous carbapenem or broad-spectrum penicillin or cephalosporin (with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ) pending culture and sensitivity data is appropriate for patients who develop nosocomial prostatitis (eg, following a procedure for which they received a prophylactic fluoroquinolone) or who have a history of infections with drug-resistant pathogens, because of the increased risk of infection with a quinolone-resistant organism.",
"   </p>",
"   <p>",
"    If available, a Gram stain of the urine can be helpful to further guide the empiric antibiotic choice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with gram-negative rods on urine Gram stain should be treated as above.",
"     </li>",
"     <li>",
"      Gram-positive cocci in chains usually indicate enterococcal infection, which can be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (500 mg orally every eight hours) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      (2 g intravenous every six hours) if parenteral therapy is indicated. Of note, these regimens are not active against most Enterococcus faecium or other ampicillin-resistant strains. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of enterococcal infections\", section on 'Approach to resistant strains'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gram-positive cocci in clusters are most often due to Staphylococcus aureus or coagulase-negative staphylococci (eg, S. epidermidis or S. saprophyticus). Effective oral antibiotics for strains that are not methicillin-resistant include cephalosporins (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      500 mg orally every six hours) or penicillinase-resistant penicillins (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"       dicloxacillin",
"      </a>",
"      500 mg orally every six hours). Choices for parenteral therapy include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      (1 g intravenous every eight hours) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      (2 g intravenous every four to six hours). If there are risk factors for, or a history of methicillin-resistant S. aureus,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg/d",
"      </span>",
"      in two divided doses with adjustments made for renal insufficiency) can be used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further changes to the empiric antibiotic regimen can be made based on susceptibility data of the isolated organism and clinical response. Of note, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    is commonly used for lower urinary tract infections in women, we avoid this agent in men with prostatitis because of concern about poor tissue penetration and risk of adverse effects from prolonged use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172459038\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients initiated on parenteral antibiotics can be switched to oral antibiotics, if drug susceptibility and patient tolerance allow, 24 to 48 hours following improvement in fever and clinical symptoms. Antibiotics should be administered for six weeks to ensure eradication of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical data on the duration of treatment for acute bacterial prostatitis are limited. We favor prolonged therapy because of limited antimicrobial penetration into the prostate and the development of protected microcolonies deep within the inflamed gland that may be difficult to reach with antimicrobials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13503308\">",
"    <span class=\"h2\">",
"     Nonantimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, acute urinary retention develops during an episode of acute prostatitis. In this setting, bladder drainage must be done by suprapubic catheterization. Passage of a catheter through the inflamed urethra into the bladder is contraindicated in patients with acute prostatitis.",
"   </p>",
"   <p>",
"    In a patient with a prostatic abscess, urological referral is indicated if the abscess is persistent after one week or more of antimicrobial therapy. In some cases, ultrasound-guided or surgical drainage may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Monitoring during therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, fever abates and dysuria disappears within two to six days after the start of therapy. Acute phase reactants (eg, sedimentation rate, C reactive protein) and the PSA, if obtained, return to normal more gradually [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/19\">",
"     19",
"    </a>",
"    ]. Clinical studies using a fluoroquinolone suggest that a negative urine culture at seven days following initiation of therapy predicts cure at the conclusion of the full course of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4776/abstract/29\">",
"     29",
"    </a>",
"    ]. We typically repeat urine culture at seven days. If it is still positive at that time, alternative therapy should be initiated, based upon in vitro susceptibility tests of the most recent isolate.",
"   </p>",
"   <p>",
"    Patients with persistently positive urine cultures should be further evaluated and treated for chronic bacterial prostatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=see_link\">",
"     \"Chronic bacterial prostatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29873?source=see_link\">",
"       \"Patient information: Prostatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1669378575\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute bacterial prostatitis is an acute infection of the prostate that typically occurs in young and middle-aged men. In most men, it is generally caused by the same organisms that cause urinary tract infections, most commonly gram-negative bacteria, especially Enterobacteriaceae (typically Escherichia coli or Proteus species). Sexually transmitted pathogens, such as Neisseria gonorrhoeae and Chlamydia trachomatis, are possible etiologies in sexually active men, who may have concomitant urethritis or epididymitis. (See",
"      <a class=\"local\" href=\"#H13503206\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute bacterial prostatitis are typically acutely ill. The most common symptoms and signs include fevers, chills, dysuria, pelvic or perineal pain, and cloudy urine. Obstructive symptoms, such as dribbling of urine, can also occur. On exam, the prostate is often warm, firm, edematous, and exquisitely tender. Common laboratory findings include peripheral leukocytosis, pyuria, and bacteriuria. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delay of antimicrobial therapy can increase the risk of secondary complications, including bacteremia, prostatic abscess, and metastatic infection (eg, spinal or sacroiliac infection). Certain underlying conditions, such as diabetes mellitus or HIV-related immunosuppression, may also predispose to the development of prostatic abscesses. (See",
"      <a class=\"local\" href=\"#H13503467\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of typical symptoms of prostatitis and the finding of an edematous and tender prostate on physical exam usually establishes the diagnosis. Digital rectal examination should be performed gently; vigorous prostate massage should be avoided since it is uncomfortable, allows no additional diagnostic or therapeutic benefit, and increases risk for bacteremia. Tenderness of the prostate on exam is generally not found in isolated UTIs or other acute causes of dysuria (eg, urethritis, epididymitis) in the absence of coexisting prostatitis. (See",
"      <a class=\"local\" href=\"#H23323217\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H172458394\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A urine Gram stain and culture should be obtained in all men suspected of having acute prostatitis to identify the bacterial etiology. Imaging studies are generally not warranted in acute bacterial prostatitis, unless there is clinical suspicion for a prostatic abscess (ie, when there are persistent clinical or laboratory abnormalities despite appropriate antimicrobial therapy). (See",
"      <a class=\"local\" href=\"#H23323217\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23323238\">",
"       'Evaluation for complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of acute bacterial prostatitis are caused by gram-negative organisms, and empiric antibiotic therapy should be directed against this class. We suggest empiric treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      or a fluoroquinolone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), unless drug resistance is suspected. The choice between these should take into account patient tolerance and regional patterns of Enterobacteriaceae drug resistance. If a urine Gram stain is available and suggests an alternate bacterial cause, initial antibiotic therapy should be directed against the identified class of organism. Parenteral antimicrobial therapy is warranted in patients who cannot tolerate oral medications, demonstrate signs of severe sepsis, or have bacteremia. Further changes to the empiric antibiotic regimen can be made based on susceptibility data of the isolated organism and clinical response. (See",
"      <a class=\"local\" href=\"#H13503301\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients initiated on parenteral antibiotics can be switched to oral antibiotics, if drug susceptibility and patient tolerance allow, 24 to 48 hours following improvement in fever and clinical symptoms. We typically use a prolonged antibiotic course (eg, six weeks) to try to ensure eradication of the infection. If the urine culture is still positive at seven days, alternative therapy should be initiated, based upon in vitro susceptibility tests of the most recent isolate. (See",
"      <a class=\"local\" href=\"#H172459038\">",
"       'Duration of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Monitoring during therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjunctive therapies include management of complications, such as acute urinary retention and prostatic abscesses. Passage of a catheter through the inflamed urethra into the bladder is contraindicated in patients with acute prostatitis. If needed, bladder drainage must be done by suprapubic catheterization. (See",
"      <a class=\"local\" href=\"#H13503308\">",
"       'Nonantimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/1\">",
"      Pontari MA, Joyce GF, Wise M, et al. Prostatitis. J Urol 2007; 177:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/2\">",
"      Johnson JR, Kuskowski MA, Gajewski A, et al. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J Infect Dis 2005; 191:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/3\">",
"      Krieger JN, Dobrindt U, Riley DE, Oswald E. Acute Escherichia coli prostatitis in previously health young men: bacterial virulence factors, antimicrobial resistance, and clinical outcomes. Urology 2011; 77:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/4\">",
"      Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 282:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/5\">",
"      Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol 1998; 159:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/6\">",
"      Wyndaele JJ. Complications of intermittent catheterization: their prevention and treatment. Spinal Cord 2002; 40:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/7\">",
"      Mosharafa AA, Torky MH, El Said WM, Meshref A. Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology 2011; 78:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/8\">",
"      Ozden E, Bostanci Y, Yakupoglu KY, et al. Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy. Urology 2009; 74:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/9\">",
"      Breyer BN, Van den Eeden SK, Horberg MA, et al. HIV status is an independent risk factor for reporting lower urinary tract symptoms. J Urol 2011; 185:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/10\">",
"      Lee LK, Dinneen MD, Ahmad S. The urologist and the patient infected with human immunodeficiency virus or with acquired immunodeficiency syndrome. BJU Int 2001; 88:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/11\">",
"      Cornia PB, Takahashi TA, Lipsky BA. The microbiology of bacteriuria in men: a 5-year study at a Veterans' Affairs hospital. Diagn Microbiol Infect Dis 2006; 56:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/12\">",
"      Mill&aacute;n-Rodr&iacute;guez F, Palou J, Bujons-Tur A, et al. Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract. World J Urol 2006; 24:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/13\">",
"      Etienne M, Chavanet P, Sibert L, et al. Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis. BMC Infect Dis 2008; 8:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/14\">",
"      Etienne M, Pestel-Caron M, Chapuzet C, et al. Should blood cultures be performed for patients with acute prostatitis? J Clin Microbiol 2010; 48:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/15\">",
"      Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis 2010; 50:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/16\">",
"      Heyse AM, Dierick J, Vanhouteghem H, et al. A case of imported melioidosis presenting as prostatitis. Infection 2003; 31:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/17\">",
"      Morse LP, Moller CC, Harvey E, et al. Prostatic abscess due to Burkholderia pseudomallei: 81 cases from a 19-year prospective melioidosis study. J Urol 2009; 182:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/18\">",
"      Smith JW, Jones SR, Reed WP, et al. Recurrent urinary tract infections in men. Characteristics and response to therapy. Ann Intern Med 1979; 91:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/19\">",
"      Gam&eacute; X, Vincendeau S, Palascak R, et al. Total and free serum prostate specific antigen levels during the first month of acute prostatitis. Eur Urol 2003; 43:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/20\">",
"      Siroky MB, Moylan R, Austen G Jr, Olsson CA. Metastatic infection secondary to genitourinary tract sepsis. Am J Med 1976; 61:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/21\">",
"      Weinberger M, Cytron S, Servadio C, et al. Prostatic abscess in the antibiotic era. Rev Infect Dis 1988; 10:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/22\">",
"      Horcajada JP, Vilana R, Moreno-Mart&iacute;nez A, et al. Transrectal prostatic ultrasonography in acute bacterial prostatitis: findings and clinical implications. Scand J Infect Dis 2003; 35:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/23\">",
"      Trauzzi SJ, Kay CJ, Kaufman DG, Lowe FC. Management of prostatic abscess in patients with human immunodeficiency syndrome. Urology 1994; 43:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/24\">",
"      Ludwig M, Schroeder-Printzen I, Schiefer HG, Weidner W. Diagnosis and therapeutic management of 18 patients with prostatic abscess. Urology 1999; 53:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/25\">",
"      Thornhill BA, Morehouse HT, Coleman P, Hoffman-Tretin JC. Prostatic abscess: CT and sonographic findings. AJR Am J Roentgenol 1987; 148:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/26\">",
"      Chia JK, Longfield RN, Cook DH, Flax BL. Computed axial tomography in the early diagnosis of prostatic abscess. Am J Med 1986; 81:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/27\">",
"      Brede CM, Shoskes DA. The etiology and management of acute prostatitis. Nat Rev Urol 2011; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/28\">",
"      Wagenlehner FM, Weidner W, Naber KG. Therapy for prostatitis, with emphasis on bacterial prostatitis. Expert Opin Pharmacother 2007; 8:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4776/abstract/29\">",
"      Arakawa S, Kamidono S. Assessment of the UTI criteria for bacterial prostatitis in Japan. Infection 1992; 20 Suppl 3:S232.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8062 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4776=[""].join("\n");
var outline_f4_42_4776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1669378575\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29437530\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13503206\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29437419\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13503467\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23323139\">",
"      - Prostatic abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23323217\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17630369\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23323238\">",
"      Evaluation for complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17630388\">",
"      Evaluation for anatomical abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172458394\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23323367\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23323375\">",
"      Indications for hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13503301\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172459038\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13503308\">",
"      Nonantimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Monitoring during therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1669378575\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8062\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8062|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/35/20023\" title=\"figure 1\">",
"      Prostate anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15479?source=related_link\">",
"      Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=related_link\">",
"      Chronic bacterial prostatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=related_link\">",
"      Chronic prostatitis/chronic pelvic pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26649?source=related_link\">",
"      Complications of Staphylococcus aureus bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39577?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations, and diagnosis of melioidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44360?source=related_link\">",
"      Evaluation of the acute scrotum in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=related_link\">",
"      Infectious causes of dysuria in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=related_link\">",
"      Lower urinary tract symptoms in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29873?source=related_link\">",
"      Patient information: Prostatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_42_4777="Liver, spleen, and pancreas injury in children with blunt abdominal trauma";
var content_f4_42_4777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Liver, spleen, and pancreas injury in children with blunt abdominal trauma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/42/4777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/42/4777/contributors\">",
"     David E Wesson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/42/4777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/42/4777/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/42/4777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/42/4777/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/42/4777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14482525\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver and spleen injuries are the most common, potentially life-threatening intraabdominal injuries in children who sustain blunt trauma. Pancreatic injury, which is less common, may result in peritonitis or a pseudocyst if a large duct is transected. The prognosis for all three types of injury depends mainly on the presence or absence of associated injuries, especially to the brain and the thorax.",
"   </p>",
"   <p>",
"    This topic will review the diagnosis and management of liver, spleen, and pancreas injuries in children with blunt abdominal trauma. The general approach to blunt abdominal trauma in children and the diagnosis and management of hollow viscus injury following pediatric blunt abdominal trauma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link\">",
"     \"Overview of blunt abdominal trauma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13001?source=see_link\">",
"     \"Hollow viscus blunt abdominal trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482532\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt abdominal trauma occurs in 10 to 15 percent of injured children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/1\">",
"     1",
"    </a>",
"    ]. Solid organ injuries are common in children who sustain major trauma, with isolated injury to the spleen occurring most frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/2\">",
"     2",
"    </a>",
"    ]. Injuries to the liver, spleen, and pancreas occur in two typical scenarios: isolated injury caused by a direct blow to the upper abdomen, or multi-system trauma caused by high-energy mechanisms (eg, motor vehicle or all-terrain vehicle crash, fall from a great height) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/1\">",
"     1",
"    </a>",
"    ]. Isolated injuries to these organs are more common, but those associated with multi-system injury are more life-threatening with reported mortality as high as 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482539\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver, spleen, and pancreas lie in the upper abdomen. They are partly protected by the ribs. This protection is less effective in children than in adults because the ribs are very pliable and because the liver and spleen may extend caudally beyond the ribs, especially in infants and toddlers. In addition, children have relatively larger viscera, less overlying fat, and weaker abdominal musculature. In children, almost all injuries to the liver, spleen, and pancreas are caused by blunt force. The mechanism can be a direct blow to the epigastrium with deformation of the abdominal wall, avulsion of the blood supply by rapid deceleration, puncture by a fractured rib, or crushing against the vertebral column.",
"   </p>",
"   <p>",
"    Because the liver and spleen are highly vascular, injuries to these organs can cause fatal blood loss either from the parenchyma or the arteries and veins that supply them. Both perform essential physiologic functions, but the spleen can be removed completely to stop bleeding when all other approaches fail. &nbsp;",
"   </p>",
"   <p>",
"    The liver has a dual blood supply via the hepatic arteries and the portal vein. Like the spleen, the liver parenchyma has a rich blood supply so that parenchymal injuries can lead to life-threatening blood loss. Blood flows from the posterior-superior surface of the liver into the IVC via the hepatic veins. Injuries to these vessels may lead to rapid exsanguination. The liver in children is relatively large and has less fibrous stroma than in adults. These differences make the child's liver more susceptible to laceration and bleeding after blunt abdominal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, the parenchyma of the pancreas is not as vascular as the liver and spleen, so pancreatic trauma rarely causes major blood loss. Pancreatic trauma may cause the release of pancreatic juice, which is rich in digestive enzymes, causing local peritoneal and retroperitoneal inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482553\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation of pediatric trauma patients should follow the standard Advanced Trauma Life Support (ATLS) protocol, with life-threatening injuries that compromise airway, breathing, and circulation addressed first (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). Assessment for abdominal injury should take place as part of the secondary survey. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H33#H33\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Abdomen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of injuries to the liver, spleen, and pancreas should be made on the basis of clinical assessment by history and physical examination confirmed by diagnostic imaging. These injuries cause harm through two basic mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding from the parenchyma of the spleen and liver or the major blood vessels that supply these organs",
"     </li>",
"     <li>",
"      Peritonitis from the release of pancreatic juice",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical assessment of children with blunt abdominal trauma is primarily the search for evidence of bleeding or peritonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9282651\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is usually a history of a direct blow to the trunk over the upper abdomen (bicycle handlebar, hockey stick jammed between the boards and abdomen, helmet \"spearing\" in football) or a high-energy mechanism, such as a high-speed motor vehicle crash or a fall from a great height. Children with solid organ injuries often, but not always, complain of pain that may be localized to the area over the injured organ or may be more generalized. With pancreatic trauma, the pain may radiate to the back and with splenic involvement, to the left shoulder (Kehr sign). In patients with multi-system trauma, a decreased level of consciousness or injuries to other parts of the body may mask abdominal involvement. A seemingly minimal force may injure children with preexisting hepatomegaly or splenomegaly. Child abuse should also be suspected in children in whom the history is absent or inadequate to explain the degree of injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19497?source=see_link&amp;anchor=H11#H11\">",
"     \"Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis\", section on 'Abdominal injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9282670\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of solid organ injury may include findings of hypovolemic shock (eg, tachycardia, decreased capillary refill time, pallor, altered mental status, decreased urine output, hypotension), abdominal contusions, or tenderness over the upper abdomen. The following findings should be noted on abdominal examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal tenderness, specific patterns may be associated with the injured organ:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Right upper quadrant tenderness or superior midline abdominal tenderness &ndash; Liver or pancreas injury",
"     </li>",
"     <li>",
"      Left upper quadrant tenderness &ndash; Splenic injury",
"     </li>",
"     <li>",
"      Epigastric tenderness &ndash; Pancreas injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal wall ecchymosis or abrasions (&ldquo;seat belt sign&rdquo; or midline abdominal bruise from a bicycle handlebar)",
"     </li>",
"     <li>",
"      Abdominal distension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gastric decompression with a nasogastric or orogastric tube facilitates abdominal examination in the multiple trauma patient and reduces the risk of aspiration of gastric contents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/6\">",
"     6",
"    </a>",
"    ]. The abdominal examination is difficult to interpret in patients with impaired neurologic status from head or spinal cord injury or substance abuse and is unreliable in determining the need for further evaluation and intervention in a significant proportion of these patients. For example, a case series of 71 children with head injury and intraabdominal injury discovered on CT or at laparotomy reported a negative physical examination in 30 patients (42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If present, blood loss great enough to cause shock will usually occur within 24 hours. For example, an observational study of 1813 children with solid organ injuries found that median time to operation was 2.4 hours with 90 percent of the 120 children undergoing surgical intervention within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/8\">",
"     8",
"    </a>",
"    ]. After 24 hours, the risk of massive bleeding decreases.",
"   </p>",
"   <p>",
"    In addition to solid organ injuries, a linear bruise across the abdomen from a seat belt is associated with injuries to the bowel, retroperitoneal vessels, spine, and spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13001?source=see_link&amp;anchor=H7836200#H7836200\">",
"     \"Hollow viscus blunt abdominal trauma in children\", section on 'Seat belt syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20903968\">",
"    <span class=\"h2\">",
"     Delayed clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, patients may present with delayed complaints and physical findings. Patients with delayed presentation of splenic injury (hemorrhage from the ruptured spleen more than 48 hours after trauma) can present with left subcostal pain; left shoulder pain; abdominal distension, rigidity, or rebound tenderness; fullness in the left upper quadrant; or anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Patients with delayed presentation of pancreatic trauma may have findings suggestive of pancreatic pseudocyst, including epigastric pain, palpable abdominal mass, peritoneal findings, and elevated lipase or amylase [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482567\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for performing specific laboratory studies in children with blunt abdominal trauma are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hematologic studies, serum chemistries, and urinalysis are adjuncts to diagnosis and are not substitutes for clinical assessment and further imaging of children with suspected trauma to the liver, spleen, or pancreas. Of the studies often obtained in these children, the following are most likely to assist with acute patient management:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematocrit",
"     </li>",
"     <li>",
"      Type and cross for packed red blood cells",
"     </li>",
"     <li>",
"      Rapid blood glucose",
"     </li>",
"     <li>",
"      Liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT])",
"     </li>",
"     <li>",
"      Serum amylase and lipase",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, an initial hematocrit and blood for type and cross are most essential, especially in children with signs of hypovolemic shock.",
"   </p>",
"   <p>",
"    Other studies commonly obtained in unstable pediatric blunt trauma victims include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H22#H22\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Laboratory studies'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR)",
"     </li>",
"     <li>",
"      Serum electrolytes",
"     </li>",
"     <li>",
"      Serum blood urea nitrogen (BUN) and creatinine",
"     </li>",
"     <li>",
"      Arterial or venous blood gas",
"     </li>",
"     <li>",
"      Blood ethanol level and urine screen for drugs of abuse (adolescents)",
"     </li>",
"     <li>",
"      Urine pregnancy test (postmenarchal females)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory studies have limited sensitivity and negative predictive value for blunt abdominal trauma, including liver, spleen, or pancreas injury. An observational study evaluated the test characteristics of the &ldquo;routine trauma panel&rdquo;, including complete blood count, serum electrolytes, glucose, liver enzymes, prothrombin time, partial thromboplastin time, and urinalysis in 83 of 241 children with blunt abdominal trauma and evidence of intraabdominal injury on computed tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/15\">",
"     15",
"    </a>",
"    ]. No single test had acceptable sensitivity or negative predictive value to be helpful in screening such patients. In this study, glucose and aspartate aminotransferase (AST) had the highest sensitivity (75 and 63 percent, respectively), and lipase had the highest positive predictive value (75 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482574\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal CT with intravenous contrast is the preferred diagnostic imaging modality to detect intraabdominal injury in hemodynamically stable children who have sustained blunt abdominal trauma. CT is sensitive and specific in diagnosing liver, and spleen injuries, which may be managed nonoperatively. CT with IV contrast alone is less sensitive for detecting pancreas injuries. (See",
"    <a class=\"local\" href=\"#H14482588\">",
"     'Liver'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14482602\">",
"     'Spleen'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14482609\">",
"     'Pancreas'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Indications for abdominal CT scan (only for use in the hemodynamically stable patient) include the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Abdominal CT'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical examination suggestive of injury (eg, abdominal tenderness, concern for child abuse)",
"     </li>",
"     <li>",
"      Seat belt sign (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13001?source=see_link&amp;anchor=H7836200#H7836200\">",
"       \"Hollow viscus blunt abdominal trauma in children\", section on 'Seat belt syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      History or mechanism of injury suggestive of intraabdominal injury in a patient with distracting injuries",
"     </li>",
"     <li>",
"      Initial serum aspartate aminotransferase (AST) &gt;200",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      or alanine aminotransferase (ALT) &gt;125",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"     </li>",
"     <li>",
"      Gross or microscopic hematuria (&ge;50 red blood cells per high powered field) in otherwise asymptomatic patients",
"     </li>",
"     <li>",
"      Declining hematocrit or hematocrit &lt;30 percent",
"     </li>",
"     <li>",
"      Unaccountable fluid or blood requirements",
"     </li>",
"     <li>",
"      Inability to perform adequate abdominal examination or serial abdominal examinations (eg, children younger than two to three years or those with substance use, head injury, altered sensorium, or planned general anesthesia) in a patient with history or mechanism suggestive of intraabdominal injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Focused assessment with sonography for trauma (FAST) is a rapid ultrasound examination of four abdominal locations: right upper quadrant, left upper quadrant, subxiphoid region, and pelvis. The primary utility of this examination for the unstable trauma patient is the detection of hemopericardium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraperitoneal fluid secondary to intraabdominal injury (IAI). For example, unstable patients with blunt abdominal trauma and intraperitoneal fluid on FAST may warrant operative intervention in lieu of computed tomography (CT) of the abdomen. In the stable patient, the presence of intraperitoneal fluid on FAST indicates the need for abdominal CT. However, a negative FAST does not have adequate sensitivity or negative predictive value to exclude intraabdominal injury, especially solid organ injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H24#H24\">",
"     \"Trauma management: Approach to the unstable child\", section on 'FAST (Focused Assessment with Sonography for Trauma)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contrast-enhanced sonography using blood pool agents appears to have higher sensitivity for solid organ injury in children than FAST. For example, a study in 27 children with blunt abdominal trauma who had both contrast-enhanced sonography and computed tomography of the abdomen with intravenous contrast, contrast-enhanced sonography had a sensitivity of 93 percent and a negative predictive value of 94 percent for 14 injuries to the spleen, liver, pancreas, kidney, and adrenal gland [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/16\">",
"     16",
"    </a>",
"    ]. However, this more labor-intensive form of ultrasound imaging is not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9282930\">",
"    <span class=\"h2\">",
"     Diagnostic peritoneal lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic peritoneal lavage (DPL) is not performed in hemodynamically stable children with suspected injury to the liver, spleen, or pancreas because most children with solid organ injury are managed nonoperatively, and intraabdominal bleeding may cause a false positive test in a significant number of such patients. Rarely, DPL may be performed to determine the need for laparotomy in a hemodynamically unstable patient with a suspected emergent, operative head injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9284271\">",
"    <span class=\"h1\">",
"     STABILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of children with suspected injury to the liver, spleen,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pancreas should adhere to the Advanced Trauma Life Support protocol for diagnosis and treatment of immediately life-threatening injuries and appropriate resuscitation (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). After the patient has been assessed, resuscitated, and stabilized, the patient should receive ongoing care directed by a trauma surgeon with pediatric expertise, when available. Because optimal care and outcomes occur when the critically injured child is initially resuscitated and subsequently managed in a pediatric trauma center (PTC), it is preferable to provide initial care in such facilities from the outset, whenever possible, or to arrange transfer to a PTC for ongoing management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H44#H44\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Definitive care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most instances, children with liver, spleen, or pancreas injuries are managed nonoperatively. (See",
"    <a class=\"local\" href=\"#H14482581\">",
"     'Definitive management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hemodynamically unstable children with blunt abdominal injury who do not improve with fluid resuscitation (normal saline or Ringer&rsquo;s lactate, 40 to 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    intravenously, maximum total volume 3 L, followed by packed red blood cells, 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    intravenously) warrant emergent exploratory laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H641707\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification systems for liver, spleen, or pancreas injury are typically based upon computed tomography (CT) images (",
"    <a class=\"graphic graphic_table graphicRef67884 \" href=\"UTD.htm?6/18/6444\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53232 \" href=\"UTD.htm?14/63/15356\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76295 \" href=\"UTD.htm?28/10/28844\">",
"     table 3",
"    </a>",
"    ), since most of these injuries are treated nonoperatively. However, the decision to operate is based upon hemodynamic stability,",
"    <strong>",
"     not",
"    </strong>",
"    CT findings. (See",
"    <a class=\"local\" href=\"#H14482581\">",
"     'Definitive management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482581\">",
"    <span class=\"h1\">",
"     DEFINITIVE MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H641878\">",
"    <span class=\"h2\">",
"     Nonoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamically stable patients can be admitted to an acute care ward, but patients who were initially hemodynamically unstable or anemic require intensive care unit monitoring. In more than 90 percent of cases, management of patients with liver or splenic injuries requires only admission to the hospital for monitoring of vital signs, hematocrit, and urinary output, combined with temporary rest and restricted activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/8,19\">",
"     8,19",
"    </a>",
"    ]. By contrast, 18 to 50 percent of pancreatic injuries require surgery at some point [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14482609\">",
"     'Pancreas'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Less than 5 percent of patients with liver or spleen injuries require a blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/21\">",
"     21",
"    </a>",
"    ]. However, those who develop hypovolemic shock or a significant drop in hemoglobin and hematocrit should receive blood as necessary. Hemodynamic instability or ongoing blood loss requiring &gt;20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of packed red blood cells (approximately equivalent to half of the blood volume) is the primary indication for operative intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Pediatric Surgical Association (APSA) has developed evidence-based clinical practice guidelines (CPG) for the treatment of clinically stable patients with isolated liver and spleen injuries, grades I-IV, (",
"    <a class=\"graphic graphic_table graphicRef67884 \" href=\"UTD.htm?6/18/6444\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53232 \" href=\"UTD.htm?14/63/15356\">",
"     table 2",
"    </a>",
"    ), based on review of 832 children cared for at 32 pediatric centers in the US (",
"    <a class=\"graphic graphic_table graphicRef78428 \" href=\"UTD.htm?43/36/44619\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Use of the CPG has been associated with lower resource utilization without evidence of significant risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prospective application of the CPG in 312 children with isolated liver or spleen injuries treated at 16 pediatric centers was associated with a significant reduction in hospital length of stay, intensive care unit (ICU) stay, repeat imaging, and duration of restriction in physical activity at each grade of injury relative to a historical control [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/24\">",
"       24",
"      </a>",
"      ]. Six patients were readmitted, but none required operation. Compliance with the CPG was achieved in 88 percent of patients.",
"     </li>",
"     <li>",
"      Use of the CPG in 107 children with isolated liver or spleen injuries at a single pediatric center showed significant reductions in length of ICU stay, days in the hospital, number of hematocrits performed, and follow-up imaging studies when compared to 116 children managed prior to adoption of the CPG at this institution [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/25\">",
"       25",
"      </a>",
"      ]. These reductions occurred despite higher degree of injury severity in the patients treated according to the CPG. No patients required urgent operation. One patient in the CPG group was readmitted. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, we suggest that clinically stable children with isolated liver and spleen injuries, grades I through IV, receive nonoperative management according to the clinical practice guidelines established by the American Pediatric Surgical Association.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H641897\">",
"    <span class=\"h2\">",
"     Angiographic embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although angiographic embolization of vascular injuries to the spleen and liver is widely used in adults, experience in children is limited to isolated case reports and case series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one pediatric case series, two splenic injuries and two liver injuries were successfully embolized [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/26\">",
"       26",
"      </a>",
"      ]. The indication for all four patients was evidence of ongoing hemorrhage (eg, decreasing hematocrit) with hemodynamic stability. No acute complications occurred (eg, arterial puncture site hematoma, catheter, or guidewire related arterial injury, contrast nephropathy, target organ ischemia, nontarget organ embolization). Late pleural effusions occurred in both children with liver injury.",
"     </li>",
"     <li>",
"      A 12 year old girl with an isolated grade IV splenic injury and vascular blush sign (arterial extravasation of intravenous contrast), who was hemodynamically unstable despite crystalloid infusion and blood transfusions, underwent successful splenic artery embolization with microcoils [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/27\">",
"       27",
"      </a>",
"      ]. At one year, the spleen size was normal and appeared to be functioning normally.",
"     </li>",
"     <li>",
"      In a case series of 21 children with blunt hepatic injury, angiographic embolization was used successfully in two patients with hemodynamic stability, but continuing hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given that hemodynamically unstable children usually warrant operation and hemorrhage resolves in most hemodynamically stable children without specific intervention, angiographic embolization for pediatric blunt abdominal trauma appears to have limited utility in children with injury to the liver, spleen, or pancreas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482588\">",
"    <span class=\"h2\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the diagnosis of liver injuries is best established by contrast-enhanced computed tomography of the abdomen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52550 \" href=\"UTD.htm?40/59/41904\">",
"     image 1",
"    </a>",
"    ), the management is dictated by the clinical course. Patients who remain hemodynamically stable can be treated nonoperatively. This is possible in &gt;90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/29\">",
"     29",
"    </a>",
"    ]. If shock that does not respond to volume replacement or massive continuing blood loss occurs, laparotomy is indicated to stop the bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482595\">",
"    <span class=\"h3\">",
"     Damage control surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operations for liver trauma can be very difficult and are best performed by experienced trauma surgeons. Exsanguinating hemorrhage may occur, so the surgeon and anesthesiologist must be prepared to respond to massive blood loss. Direct control of the bleeding is ideal, but this may not be possible. Massive bleeding may lead to shock, hypothermia, coagulopathy, hypocalcemia, and lactic acidosis. In this situation, damage control with perihepatic packing to tamponade the bleeding, temporary closure of the abdomen, and return to the ICU to restore physiological stability is currently the preferred course of action (",
"    <a class=\"graphic graphic_table graphicRef55259 \" href=\"UTD.htm?19/37/20059\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/30\">",
"     30",
"    </a>",
"    ]. Once physiologic stability is achieved, the child undergoes reoperation with packing change, blood clot removal, definitive repair of injuries, and abdominal closure. In one small series of 22 children with refractory hepatic hemorrhage (13 due to blunt trauma), damage control surgery stopped hemorrhage in 21 patients and 18 patients survived [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/31\">",
"     31",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482602\">",
"    <span class=\"h2\">",
"     Spleen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast-enhanced computed tomography of the abdomen is the best way to establish the diagnosis of splenic injury (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74018 \" href=\"UTD.htm?43/41/44688\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62296 \" href=\"UTD.htm?27/16/27904\">",
"     image 3",
"    </a>",
"    ). However, the management is dictated by the clinical course; not by the injury grade or the grade of injury present on the CT, including the presence or absence of an arterial blush (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51192 \" href=\"UTD.htm?42/4/43073\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Patients who remain hemodynamically stable can be treated nonoperatively. This is possible in &gt;90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/8\">",
"     8",
"    </a>",
"    ]. There is no evidence that nonoperative treatment increases the need for blood transfusion, lengthens hospital stay, or results in missed intraabdominal injuries. Less than 5 percent of patients with isolated splenic injuries ever require a blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no generally accepted guidelines defining when operative intervention is indicated. One criterion reported more than 20 years ago is the need to replace more than half of the estimated circulating blood volume (approximately 20",
"    <span class=\"nowrap\">",
"     ml/kg",
"    </span>",
"    packed red blood cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/17\">",
"     17",
"    </a>",
"    ]. No other specific indication has been suggested. Children with a spleen injury, who do require operative intervention, almost always declare themselves in the first 12 hours after injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/8\">",
"     8",
"    </a>",
"    ]. Delayed rupture of the spleen in children is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At operation, attempts should be made to salvage the spleen, especially when there are no other significant intraabdominal injuries. In some cases, this can be accomplished by direct repair or partial splenectomy (leaving at least one-third of the spleen with an intact arterial blood supply). However, splenectomy is often the best option, especially when:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There are other significant intraabdominal injuries that require repair",
"     </li>",
"     <li>",
"      The patient is hemodynamically unstable",
"     </li>",
"     <li>",
"      The spleen is damaged beyond repair",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Splenectomy patients must be informed about the risk of post-splenectomy infection. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?18/24/18818?source=see_link\">",
"     \"Patient information: Preventing severe infection after splenectomy (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of sepsis in the asplenic patient includes immunization, antibiotic prophylaxis, and anticipatory antibiotics when patients develop a febrile illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482609\">",
"    <span class=\"h2\">",
"     Pancreas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major pancreatic injuries are much less common than liver or spleen injuries. The clinical features include a history of a direct blow to the epigastrium with local pain and tenderness. The serum amylase and lipase are usually elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/36\">",
"     36",
"    </a>",
"    ]. The most useful test for suspected pancreatic trauma is computed tomography (CT) with fine cuts through the pancreas. Endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance cholangiopancreatography (MRCP) does have a role when a major duct disruption is suspected based upon clinical findings and imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Pancreatic injuries fall into three main groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Injury without major ductal disruption",
"      </strong>",
"      &ndash; This injury type comprises the largest group of patients with pancreatic trauma. Most cases have simple contusions or hematomas, although some probably have parenchymal disruption. The diagnosis is usually suspected on the basis of elevated serum amylase and lipase levels and is confirmed by CT, which shows swelling and hemorrhage in and around the pancreas, but no evidence of transection or other major parenchymal or ductal disruption. The treatment is nonoperative, including restriction of oral intake initially, intravenous hydration, and parenteral nutrition. For example, in a case series of 43 children with pancreatic injury after blunt trauma, the 18 children with grade I injuries were all managed nonoperatively without complications [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Injury with major ductal disruption",
"      </strong>",
"      &ndash; Pancreatic trauma with ductal disruption is difficult to recognize, although it is often suggested by CT. Reports have supported the use of ERCP or MRCP to confirm the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. If recognized early, distal duct disruption can be treated by distal pancreatectomy; proximal injuries can usually be managed with gut rest and observation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/41\">",
"       41",
"      </a>",
"      ], although some experts have recommended proximal ductal stenting [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/38\">",
"       38",
"      </a>",
"      ]. Even if missed at an early stage, these injuries almost always resolve with gut rest and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      , although the course may be prolonged over many weeks. Pseudocysts develop in up to 50 percent of children with ductal disruption who are initially treated nonoperatively and up to 10 percent subsequently require surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pseudocyst",
"      </strong>",
"      &ndash; These patients present with anorexia, vomiting, weight loss, abdominal pain and tenderness, and a palpable upper abdominal mass, days to weeks post-injury. CT or ultrasound can be used to confirm the diagnosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69324 \" href=\"UTD.htm?6/29/6608\">",
"       image 5",
"      </a>",
"      ). It is thought that these patients most likely suffered a major duct disruption at the time of the original injury, which had either been unsuspected or missed on the original diagnostic images. The treatment is conservative with gut rest, parenteral nutrition, and observation by serial ultrasound. Some resolve spontaneously, while the rest usually respond to external or internal drainage after a period of four to six weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482637\">",
"    <span class=\"h1\">",
"     PITFALLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common error in the management of liver and spleen injuries is failure to recognize life-threatening bleeding at an early stage. The critical period for bleeding is the first 12 hours after injury. Delayed hemorrhage is a rare event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482644\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short and long-term outcome depends mainly on the presence or absence of associated injuries. Early mortality is related to the patient&rsquo;s overall severity of injury and occurs in up to 12 percent of children with blunt abdominal injury and multiple system trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/3\">",
"     3",
"    </a>",
"    ]. If major bleeding does not occur, or if it is treated promptly, a rapid and complete recovery of organ function is the rule. Rare late complications include hematobilia or infected biloma after liver trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/44\">",
"     44",
"    </a>",
"    ] and splenic pseudocyst after splenic trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/42/4777/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Late sequelae of pancreatic trauma primarily consist of pseudocysts and are not uncommon. In patients who undergo splenectomy, there is a small, but definite risk of post-splenectomy sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and management of sepsis in the asplenic patient\", section on 'Incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14482651\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver and spleen injuries are the most common, potentially life-threatening intraabdominal injuries in children who sustain blunt trauma. Pancreatic injury, which is less common, may result in peritonitis or a pseudocyst if a large duct is transected. (See",
"      <a class=\"local\" href=\"#H14482532\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H587479\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial evaluation of pediatric trauma patients should follow the standard Advanced Trauma Life Support (ATLS) protocol, with life-threatening injuries that compromise airway, breathing, and circulation addressed first (",
"      <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"       figure 1",
"      </a>",
"      ). Assessment for abdominal injury should take place as part of the secondary survey. (See",
"      <a class=\"local\" href=\"#H14482553\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H33#H33\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Abdomen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with liver, spleen, or pancreas injury usually have a history of a direct blow to the trunk over the upper abdomen (bicycle handlebar, hockey stick jammed between the boards and abdomen, helmet \"spearing\" in football) or a high-energy mechanism, such as a high-speed motor vehicle crash or a fall from a great height. (See",
"      <a class=\"local\" href=\"#H9282651\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical findings include local pain and tenderness over the upper abdomen, shoulder pain, or signs of shock from blood loss. Altered mental status or multiple traumatic injuries may mask significant injury to the liver, spleen, or pancreas. (See",
"      <a class=\"local\" href=\"#H9282651\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9282670\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An initial hematocrit and blood for type and cross are the most essential laboratory studies, especially in children with signs of hypovolemic shock. (See",
"      <a class=\"local\" href=\"#H14482567\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the patient has been assessed, resuscitated, and stabilized the patient should receive ongoing care directed by a trauma surgeon with pediatric expertise. Because optimal care and outcomes occur when the critically injured child is initially resuscitated and subsequently managed in a pediatric trauma center (PTC), it is preferable to provide initial care in such facilities from the outset, whenever possible, or to arrange transfer to a PTC for ongoing management. (See",
"      <a class=\"local\" href=\"#H9284271\">",
"       'Stabilization'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H44#H44\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Definitive care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal CT with intravenous contrast is the single most useful diagnostic test for liver, spleen, and pancreas injuries. (see",
"      <a class=\"local\" href=\"#H14482574\">",
"       'Imaging'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      When a major pancreatic injury is suspected based upon computed tomography findings, endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance cholangiopancreatography (MRCP) may be used to determine whether one of the major pancreatic ducts has been disrupted. (See",
"      <a class=\"local\" href=\"#H14482609\">",
"       'Pancreas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H587487\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that clinically stable children with isolated liver and spleen injuries, grades I through IV (",
"      <a class=\"graphic graphic_table graphicRef67884 \" href=\"UTD.htm?6/18/6444\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53232 \" href=\"UTD.htm?14/63/15356\">",
"       table 2",
"      </a>",
"      ), receive nonoperative management according to the clinical practice guidelines established by the American Pediatric Surgical Association (",
"      <a class=\"graphic graphic_table graphicRef78428 \" href=\"UTD.htm?43/36/44619\">",
"       table 4",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H641878\">",
"       'Nonoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most children with liver and spleen injuries and in the majority of children with pancreas injuries, complete healing will occur without any direct intervention. Thus, definitive management consists of hospital admission with careful and frequent monitoring of vital signs, urine output, and hematocrit. (See",
"      <a class=\"local\" href=\"#H14482581\">",
"       'Definitive management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main indication for surgery is massive or continuing blood loss in patients with liver or spleen injury that is unresponsive to administration of intravenous fluids and blood, or evidence of major parenchymal or ductal disruption in patients with pancreas injury. (See",
"      <a class=\"local\" href=\"#H14482588\">",
"       'Liver'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14482602\">",
"       'Spleen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14482609\">",
"       'Pancreas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/1\">",
"      Gaines BA. Intra-abdominal solid organ injury in children: diagnosis and treatment. J Trauma 2009; 67:S135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/2\">",
"      Wilson RH, Moorehead RJ. Management of splenic trauma. Injury 1992; 23:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/3\">",
"      Pariset JM, Feldman KW, Paris C. The pace of signs and symptoms of blunt abdominal trauma to children. Clin Pediatr (Phila) 2010; 49:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/4\">",
"      Schafermeyer R. Pediatric trauma. Emerg Med Clin North Am 1993; 11:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/5\">",
"      Oldham KT, Guice KS, Ryckman F, et al. Blunt liver injury in childhood: evolution of therapy and current perspective. Surgery 1986; 100:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/6\">",
"      Rance CH, Singh SJ, Kimble R. Blunt abdominal trauma in children. J Paediatr Child Health 2000; 36:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/7\">",
"      Miller D, Garza J, Tuggle D, et al. Physical examination as a reliable tool to predict intra-abdominal injuries in brain-injured children. Am J Surg 2006; 192:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/8\">",
"      Nance ML, Holmes JH 4th, Wiebe DJ. Timeline to operative intervention for solid organ injuries in children. J Trauma 2006; 61:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/9\">",
"      Hoffman MA, Spence LJ, Wesson DE, et al. The pediatric passenger: trends in seatbelt use and injury patterns. J Trauma 1987; 27:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/10\">",
"      Young KD, Seidel JS. Delayed diagnosis of splenic injury after falls from less than 10 feet. Pediatr Emerg Care 1998; 14:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/11\">",
"      McIndoe, AH. Delayed heamorrhage following traumatic rupture of the spleen. Br J Surg 1931; 20:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/12\">",
"      Lepp&auml;niemi A, Haapiainen R, Standertskj&ouml;ld-Nordenstam CG, et al. Delayed presentation of blunt splenic injury. Am J Surg 1988; 155:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/13\">",
"      Simpson RA, Ajuwon R. Occult splenic injury: delayed presentation manifesting as jaundice. Emerg Med J 2001; 18:504.",
"     </a>",
"    </li>",
"    <li>",
"     Saladino RA, Lund DP. Abdominal trauma. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1453.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/15\">",
"      Capraro AJ, Mooney D, Waltzman ML. The use of routine laboratory studies as screening tools in pediatric abdominal trauma. Pediatr Emerg Care 2006; 22:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/16\">",
"      Valentino M, Serra C, Pavlica P, et al. Blunt abdominal trauma: diagnostic performance of contrast-enhanced US in children--initial experience. Radiology 2008; 246:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/17\">",
"      Wesson DE, Filler RM, Ein SH, et al. Ruptured spleen--when to operate? J Pediatr Surg 1981; 16:324.",
"     </a>",
"    </li>",
"    <li>",
"     Waltzman, ML, Mooney, DP. Major Trauma. In: The Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher, GR, Ludwig, S (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2010. p.1244.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/19\">",
"      Tataria M, Nance ML, Holmes JH 4th, et al. Pediatric blunt abdominal injury: age is irrelevant and delayed operation is not detrimental. J Trauma 2007; 63:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/20\">",
"      Holmes JH 4th, Wiebe DJ, Tataria M, et al. The failure of nonoperative management in pediatric solid organ injury: a multi-institutional experience. J Trauma 2005; 59:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/21\">",
"      Davies DA, Pearl RH, Ein SH, et al. Management of blunt splenic injury in children: evolution of the nonoperative approach. J Pediatr Surg 2009; 44:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/22\">",
"      Stylianos S. Evidence-based guidelines for resource utilization in children with isolated spleen or liver injury. The APSA Trauma Committee. J Pediatr Surg 2000; 35:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/23\">",
"      Stylianos S. Outcomes from pediatric solid organ injury: role of standardized care guidelines. Curr Opin Pediatr 2005; 17:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/24\">",
"      Stylianos S. Compliance with evidence-based guidelines in children with isolated spleen or liver injury: a prospective study. J Pediatr Surg 2002; 37:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/25\">",
"      Leinwand MJ, Atkinson CC, Mooney DP. Application of the APSA evidence-based guidelines for isolated liver or spleen injuries: a single institution experience. J Pediatr Surg 2004; 39:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/26\">",
"      Kiankhooy A, Sartorelli KH, Vane DW, Bhave AD. Angiographic embolization is safe and effective therapy for blunt abdominal solid organ injury in children. J Trauma 2010; 68:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/27\">",
"      Naess PA, Gaarder C, Dormagen JB. Nonoperative management of pediatric splenic injury with angiographic embolization. J Pediatr Surg 2005; 40:e63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/28\">",
"      Ohtsuka Y, Iwasaki K, Okazumi S, et al. Management of blunt hepatic injury in children: usefulness of emergency transcatheter arterial embolization. Pediatr Surg Int 2003; 19:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/29\">",
"      Landau A, van As AB, Numanoglu A, et al. Liver injuries in children: the role of selective non-operative management. Injury 2006; 37:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/30\">",
"      David Richardson J, Franklin GA, Lukan JK, et al. Evolution in the management of hepatic trauma: a 25-year perspective. Ann Surg 2000; 232:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/31\">",
"      Stylianos S. Abdominal packing for severe hemorrhage. J Pediatr Surg 1998; 33:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/32\">",
"      Cloutier DR, Baird TB, Gormley P, et al. Pediatric splenic injuries with a contrast blush: successful nonoperative management without angiography and embolization. J Pediatr Surg 2004; 39:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/33\">",
"      Davies DA, Ein SH, Pearl R, et al. What is the significance of contrast \"blush\" in pediatric blunt splenic trauma? J Pediatr Surg 2010; 45:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/34\">",
"      Lynn KN, Werder GM, Callaghan RM, et al. Pediatric blunt splenic trauma: a comprehensive review. Pediatr Radiol 2009; 39:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/35\">",
"      Davies DA, Fecteau A, Himidan S, et al. What's the incidence of delayed splenic bleeding in children after blunt trauma? An institutional experience and review of the literature. J Trauma 2009; 67:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/36\">",
"      Herman R, Guire KE, Burd RS, et al. Utility of amylase and lipase as predictors of grade of injury or outcomes in pediatric patients with pancreatic trauma. J Pediatr Surg 2011; 46:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/37\">",
"      Hall RI, Lavelle MI, Venables CW. Use of ERCP to identify the site of traumatic injuries of the main pancreatic duct in children. Br J Surg 1986; 73:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/38\">",
"      Canty TG Sr, Weinman D. Treatment of pancreatic duct disruption in children by an endoscopically placed stent. J Pediatr Surg 2001; 36:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/39\">",
"      Houben CH, Ade-Ajayi N, Patel S, et al. Traumatic pancreatic duct injury in children: minimally invasive approach to management. J Pediatr Surg 2007; 42:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/40\">",
"      Wood JH, Partrick DA, Bruny JL, et al. Operative vs nonoperative management of blunt pancreatic trauma in children. J Pediatr Surg 2010; 45:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/41\">",
"      Wales PW, Shuckett B, Kim PC. Long-term outcome after nonoperative management of complete traumatic pancreatic transection in children. J Pediatr Surg 2001; 36:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/42\">",
"      de Blaauw I, Winkelhorst JT, Rieu PN, et al. Pancreatic injury in children: good outcome of nonoperative treatment. J Pediatr Surg 2008; 43:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/43\">",
"      Burnweit C, Wesson D, Stringer D, Filler R. Percutaneous drainage of traumatic pancreatic pseudocysts in children. J Trauma 1990; 30:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/44\">",
"      Nellensteijn D, Porte RJ, van Zuuren W, et al. Paediatric blunt liver trauma in a Dutch level 1 trauma center. Eur J Pediatr Surg 2009; 19:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/45\">",
"      Kristoffersen KW, Mooney DP. Long-term outcome of nonoperative pediatric splenic injury management. J Pediatr Surg 2007; 42:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/42/4777/abstract/46\">",
"      Moore HB, Vane DW. Long-term follow-up of children with nonoperative management of blunt splenic trauma. J Trauma 2010; 68:522.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13899 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4777=[""].join("\n");
var outline_f4_42_4777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14482651\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14482525\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14482532\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14482539\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14482553\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9282651\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9282670\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20903968\">",
"      Delayed clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14482567\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14482574\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9282930\">",
"      Diagnostic peritoneal lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9284271\">",
"      STABILIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H641707\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14482581\">",
"      DEFINITIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H641878\">",
"      Nonoperative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H641897\">",
"      Angiographic embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14482588\">",
"      Liver",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14482595\">",
"      - Damage control surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14482602\">",
"      Spleen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14482609\">",
"      Pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14482637\">",
"      PITFALLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14482644\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14482651\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H587479\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H587487\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13899|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/59/41904\" title=\"diagnostic image 1\">",
"      Traumatic liver laceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/41/44688\" title=\"diagnostic image 2\">",
"      Traumatic spleen laceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/16/27904\" title=\"diagnostic image 3\">",
"      Grade V traumatic laceration of the spleen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/4/43073\" title=\"diagnostic image 4\">",
"      Ruptured spleen with arterial blush",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/29/6608\" title=\"diagnostic image 5\">",
"      Pancreatic pseudocyst after blunt trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13899|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 1\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13899|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/18/6444\" title=\"table 1\">",
"      Spleen injury scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/63/15356\" title=\"table 2\">",
"      Liver injury scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/10/28844\" title=\"table 3\">",
"      Pancreatic organ injury scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/36/44619\" title=\"table 4\">",
"      Resource use in children with liver or spleen injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/37/20059\" title=\"table 5\">",
"      Damage control surgery for liver injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19497?source=related_link\">",
"      Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=related_link\">",
"      Clinical features and management of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13001?source=related_link\">",
"      Hollow viscus blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=related_link\">",
"      Overview of blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/24/18818?source=related_link\">",
"      Patient information: Preventing severe infection after splenectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_42_4778="Tacrolimus (systemic): Drug information";
var content_f4_42_4778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tacrolimus (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/14/40165?source=see_link\">",
"    see \"Tacrolimus (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/51/4921?source=see_link\">",
"    see \"Tacrolimus (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9559505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9559510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hecoria&trade;;",
"     </li>",
"     <li>",
"      Prograf&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9559511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advagraf&reg;;",
"     </li>",
"     <li>",
"      Prograf&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9564525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcineurin Inhibitor;",
"     </li>",
"     <li>",
"      Immunosuppressant Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9564218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of organ rejection in transplant recipients:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     The initial dose of tacrolimus should begin no sooner than 6 hours after liver and heart transplant and within 24 hours of kidney transplant (but may be delayed until renal function has recovered). Adjunctive therapy with corticosteroids is recommended early post-transplant. I.V. route should only be used in patients not able to take oral medications and continued only until oral medication can be tolerated; anaphylaxis has been reported with I.V. administration. If switching from I.V. to oral, the oral dose should be started 8-12 hours after stopping the infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liver transplant:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial dose: 0.1-0.15 mg/kg/day in 2 divided doses, given every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Initial dose: 0.03-0.05 mg/kg/day as a continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart transplant:",
"     </b>",
"     Use in combination with azathioprine or mycophenolate mofetil is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial dose: 0.075 mg/kg/day in 2 divided doses, given every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Initial dose: 0.01 mg/kg/day as a continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kidney transplant:",
"     </b>",
"     Use in combination with azathioprine or mycophenolate mofetil is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     U.S. labeling: Initial dose: 0.2 mg/kg/day in combination with azathioprine",
"     <b>",
"      or",
"     </b>",
"     0.1 mg/kg/day in combination with mycophenolate mofetil. Administer in 2 divided doses, given every 12 hours; African-American patients may require larger doses to maintain trough concentration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Prograf&reg;:  Initial: 0.2-0.3 mg/kg/day in 2 divided doses, given every 12 hours in combination with corticosteroids and other immunosuppressive agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Advagraf&reg;: Initial: 0.15-0.2 mg/kg/day. Administer once daily in combination with corticosteroids and mycophenolate mofetil (MMF) in",
"     <i>",
"      de novo",
"     </i>",
"     kidney transplant recipients.  Antibody induction therapy should also be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Conversion from Prograf&reg; to Advagraf&reg;: Initiate Advagraf&reg; therapy using previously established total daily dose of Prograf&reg;. Administer once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Initial dose: 0.03-0.05 mg/kg/day as a continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of graft-versus-host disease (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Convert from I.V. to oral dose (1:4 ratio): Multiply total daily I.V. dose times 4 and administer in 2 divided oral doses per day, every 12 hours (Uberti, 1999; Yanik, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Initial:  0.03 mg/kg/day (based on lean body weight) as continuous infusion. Treatment should begin at least 24 hours prior to stem cell infusion and continued only until oral medication can be tolerated (Przepiorka, 1999; Yanik, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Canadian labeling (not in U.S. labeling):",
"     <i>",
"      Oral:",
"     </i>",
"     3 mg once daily; carefully monitor serum creatinine during therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of graft-versus-host disease (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     0.06 mg/kg twice daily (Furlong, 2000; Przepiorka, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Initial: 0.03 mg/kg/day (based on lean body weight) as continuous infusion (Furlong, 2000; Przepiorka, 1999)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9564217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/51/4921?source=see_link\">",
"      see \"Tacrolimus (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liver transplant:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial dose: 0.15-0.20 mg/kg/day in 2 divided doses, given every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Initial dose: 0.03-0.05 mg/kg/day as a continuous infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The initial dose of tacrolimus should begin no sooner than 6 hours after liver and heart transplant and within 24 hours of kidney transplant (but may be delayed until renal function has recovered). Adjunctive therapy with corticosteroids is recommended early post-transplant. I.V. route should only be used in patients not able to take oral medications and continued only until oral medication can be tolerated; anaphylaxis has been reported with I.V. administration. If switching from I.V. to oral, the oral dose should be started 8-12 hours after stopping the infusion.  Patients without pre-existing renal or hepatic dysfunction have required (and tolerated) higher doses than adults to achieve similar blood concentrations. It is recommended that therapy be initiated at the",
"     <b>",
"      <i>",
"       high end",
"      </i>",
"     </b>",
"     of the recommended adult I.V. and oral dosing ranges; dosage adjustments may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of graft-vs-host disease (unlabeled use):",
"     </b>",
"     Oral, I.V.: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9564219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9564220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Evidence suggests that lower doses should be used; patients should receive doses at the lowest value of the recommended I.V. and oral dosing ranges; further reductions in dose below these ranges may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kidney transplant: Tacrolimus therapy in patients with postoperative oliguria should begin no sooner than 6 hours and within 24 hours post-transplant, but may be delayed until renal function has recovered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Not removed by hemodialysis; supplemental dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Significant drug removal is unlikely based on physiochemical characteristics.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9564221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of tacrolimus in liver transplant recipients experiencing post-transplant hepatic impairment may be associated with increased risk of developing renal insufficiency related to high whole blood levels of tacrolimus. The presence of moderate-to-severe hepatic dysfunction (serum bilirubin &gt;2 mg/dL; Child-Pugh score &ge;10) appears to affect the metabolism of tacrolimus. The half-life of the drug was prolonged and the clearance reduced after I.V. administration. The bioavailability of tacrolimus was also increased after oral administration. The higher plasma concentrations as determined by ELISA, in patients with severe hepatic dysfunction are probably due to the accumulation of metabolites of lower activity. These patients should be monitored closely and dosage adjustments should be considered. Some evidence indicates that lower doses could be used in these patients.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9564277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 0.5 mg, 1 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hecoria&trade;: 0.5 mg, 1 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prograf&reg;: 0.5 mg, 1 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prograf&reg;: 5 mg/mL (1 mL) [contains dehydrated ethanol 80%, polyoxyl 60 hydrogenated castor oil]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13262301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advagraf&reg;: 0.5 mg, 1 mg, 3 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9559517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9559509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088996.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088996.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9564223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: If I.V. administration is necessary, administer by continuous infusion only. Do not use PVC tubing when administering diluted solutions. Tacrolimus is usually intended to be administered as a continuous infusion over 24 hours.  Do not mix with solutions with a pH &ge;9 (eg, acyclovir or ganciclovir) due to chemical degradation of tacrolimus (use different ports in multilumen lines). Do not alter dose with concurrent T-tube clamping. Adsorption of the drug to PVC tubing may become clinically significant with low concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with or without food; be consistent with timing and composition of meals if GI intolerance occurs and administration with food becomes necessary (per manufacturer). If dosed once daily, administer in the morning. If dosed twice daily, doses should be 12 hours apart. If the morning and evening doses differ, the larger dose (differences are never &gt;0.5-1 mg) should be given in the morning. If dosed 3 times/day, separate doses by 8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Combination therapy with everolimus for liver transplantation: Administer tacrolimus at the same time as everolimus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Advagraf&reg;: Canadian labeling recommends that missed doses may be taken up to 14 hours after scheduled time; if &gt;14 hours, resume at next regularly scheduled time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent - use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9564188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS (only in glass or polyethylene containers).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aminophylline, amphotericin B, ampicillin, ampicillin/sulbactam, anidulafungin, benztropine, calcium gluconate, caspofungin, cefazolin, cefotetan, ceftazidime, ceftriaxone, cefuroxime, chloramphenicol, cimetidine, ciprofloxacin, clindamycin, dexamethasone sodium phosphate, digoxin, diphenhydramine, dobutamine, dopamine, doripenem, doxycycline, erythromycin lactobionate, esmolol, fluconazole, furosemide, gentamicin, haloperidol, heparin, hydrocortisone sodium succinate, hydromorphone, imipenem/cilastatin, insulin (regular), isoproterenol, leucovorin calcium, lorazepam, methylprednisolone sodium succinate, metoclopramide, metronidazole, micafungin, morphine, multivitamins, mycophenolate, nitroglycerin, nitroprusside, oxacillin, penicillin G potassium, phenytoin, piperacillin, potassium chloride, propranolol, ranitidine, sodium bicarbonate, tobramycin, trimethoprim/sulfamethoxazole, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, ganciclovir, phenytoin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9559518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Prevention of organ rejection in heart (Prograf&reg; only), and kidney or liver (Hecoria&trade;, Prograf&reg;) transplant recipients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prograf&reg;: Prevention of organ rejection in heart, kidney, or liver transplant recipients; treatment of refractory rejection in kidney or liver transplant recipients; treatment of active rheumatoid arthritis in adult patients nonresponsive to disease-modifying antirheumatic drug (DMARD) therapy or when DMARD therapy is inappropriate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advagraf&reg;: Prevention of organ rejection in kidney transplant recipients",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9559520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of organ rejection in lung, small bowel transplant recipients; prevention and treatment of graft-versus-host disease (GVHD) in allogenic hematopoietic stem cell transplantation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9559508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Prograf&reg; may be confused with Gengraf&reg;, PROzac&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tacrolimus may be confused with everolimus, pimecrolimus, sirolimus, temsirolimus",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9559543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported for kidney, liver, and heart transplantation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;15%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (13% to 62%), edema (peripheral 11% to 36%), chest pain (19%), edema (18%), pericardial effusion (heart transplant 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (24% to 64%), insomnia (30% to 64%), pain (24% to 63%), fever (19% to 48%), postprocedural pain (kidney transplant 29%), dizziness (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (15% to 36%), rash (10% to 24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: New-onset diabetes after transplant (75% kidney transplant), hypophosphatemia (28% to 49%), hypomagnesemia (16% to 48%), hyperglycemia (21% to 47%), hyperkalemia (13% to 45%), hyperlipemia (10% to 31%), hypokalemia (13% to 29%), diabetes mellitus (24% to 26%), post-transplant diabetes mellitus (heart transplant 13% to 22%; kidney transplant 20%; liver transplant 11% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (25% to 72%), abdominal pain (29% to 59%), nausea (32% to 46%), constipation (23% to 36%), anorexia (7% to 34%), vomiting (14% to 29%), dyspepsia (18% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (16% to 34%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (5% to 50%), leukopenia (13% to 48%), leukocytosis (8% to 32%), thrombocytopenia (14% to 24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests abnormal (6% to 36%), ascites (7% to 27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Incision site complication (kidney transplant 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (15% to 56%; heart transplant 15%), weakness (11% to 52%), paresthesia (17% to 40%), back pain (17% to 30%), arthralgia (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Abnormal kidney function (36% to 56%), creatinine increased (23% to 45%), BUN increased (12% to 30%), oliguria (18% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Atelectasis (5% to 28%), pleural effusion (30% to 36%), dyspnea (5% to 29%), cough increased (18%), bronchitis (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (24% to 45%), CMV infection (heart transplant 32%), graft dysfunction (kidney transplant 24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;15%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Abnormal ECG (QRS or ST segment abnormal), arrhythmia, atrial fibrillation, atrial flutter, bradycardia, cardiopulmonary failure, deep thrombophlebitis, heart failure, heart rate decreased, hemorrhage, hemorrhagic stroke, hypervolemia, hypotension, orthostatic hypotension, peripheral vascular disorder, phlebitis, syncope, tachycardia, thrombosis, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, abnormal thinking, agitation, amnesia, anxiety, chills, confusion, depression, emotional lability, encephalopathy, flaccid paralysis, hallucinations, mood elevated, nervousness, psychosis, quadriparesis, seizure, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, bruising, cellulitis, exfoliative dermatitis, fungal dermatitis, hirsutism, photosensitivity reaction, skin discoloration, skin disorder, skin neoplasm, skin ulcer, wound healing impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, alkalosis, bicarbonate decreased, Cushing's syndrome, dehydration, gout, hypercholesterolemia, hyper-/hypocalcemia, hyponatremia, hyperphosphatemia, hyperuricemia, hypoproteinemia, serum iron decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased, cramps, duodenitis, dysphagia, enlarged abdomen, esophagitis (including ulcerative), flatulence, gastritis, gastroesophagitis, GI perforation/hemorrhage, ileus, oral moniliasis, pancreatic pseudocyst, rectal disorder, stomatitis, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Bladder spasm, cystitis, dysuria, nocturia, urge incontinence, urinary frequency, urinary incontinence, urinary retention, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Coagulation disorder, decreased prothrombin, hypochromic anemia, polycythemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, bilirubinemia, cholangitis, cholestatic jaundice, GGT increased, hepatitis (including granulomatous), jaundice, LDH increased, liver damage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hypertonia, incoordination, joint disorder, leg cramps, monoparesis, myalgia, myasthenia, myoclonus, nerve compression, neuropathy, osteoporosis, quadriparesis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision, amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear pain, otitis media, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Acute renal failure, albuminuria, BK nephropathy, hematuria, hydronephrosis, renal tubular necrosis, toxic nephropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, emphysema, lung disorder, lung function decreased, pharyngitis, pneumonia, pneumothorax, pulmonary edema, respiratory disorder, rhinitis, sinusitis, voice alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Abscess, abnormal healing, allergic reaction, crying, diaphoresis, flu-like syndrome, generalized spasm, hernia, herpes simplex, hiccups, peritonitis, sepsis, writing impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (limited to important or life-threatening): Agranulocytosis, anaphylaxis, anaphylactoid reaction, angioedema, ARDS, atrial flutter, basal cell carcinoma, bile duct stenosis, blindness, cardiac arrest, cerebral infarction, cerebrovascular accident, deafness, delirium, DIC, hemiparesis, hemolytic anemia, hemolytic-uremic syndrome, hemorrhagic cystitis, hepatic necrosis, hepatotoxicity, interstitial lung disease, leukoencephalopathy, lymphoproliferative disorder (related to EBV), malignant melanoma, myocardial hypertrophy (associated with ventricular dysfunction; reversible upon discontinuation), MI, neutropenia, osteomyelitis, pancreatitis (hemorrhagic and necrotizing), pancytopenia, posterior reversible encephalopathy syndrome (PRES), progressive multifocal leukoencephalopathy (PML), quadriplegia, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, respiratory failure, septicemia, squamous cell carcinoma, Stevens-Johnson syndrome, toxic epidermal necrolysis, thrombocytopenic purpura, torsade de pointes, TTP, veno-occlusive hepatic disease, venous thrombosis, ventricular fibrillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) have been reported (with concurrent sirolimus).",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9559526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tacrolimus or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9559527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: Injection: Hypersensitivity reactions, including anaphylaxis, have been reported. Since the injection contains a castor oil derivative, its use should be limited to patients unable to take capsules. Monitor patient for a minimum of 30 minutes after initiation of infusion and then at frequent intervals; discontinue infusion if anaphylaxis occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus (post-transplant): The risk for new-onset diabetes and insulin-dependent post-transplant diabetes mellitus (PTDM) is increased with tacrolimus use after transplantation, including in patients without pretransplant history of diabetes mellitus; insulin dependence may be reversible; increased risk in African-American and Hispanic kidney transplant patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Mild-to-severe hyperkalemia may occur; monitor potassium levels and avoid use of potassium-sparing diuretics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Immunosuppressant agents, including tacrolimus, increase the risk of infection; the risk of developing bacterial, viral (including CMV), fungal, and protozoal infections, including opportunistic infections, is increased.",
"     </b>",
"     Infections may result in serious and fatal outcomes. Latent viral infections may be activated, including BK virus (associated with polyoma virus-associated nephropathy [PVAN]) and JC virus (associated with progressive multifocal leukoencephalopathy [PML]); may result in serious adverse effects. The risk of CMV disease is increased for patients who are CMV-seronegative prior to transplant and receive a graft from a CMV-seropositive donor. Consider reduction in immunosuppression if PVAN, PML, CMV viremia and/or CMV disease occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Immunosuppressant  agents, including tacrolimus, may be associated with the development of lymphoma and other malignancies (predominantly skin malignancies).",
"     </b>",
"     The risk for malignancies is related to intensity/duration of therapy. Limit sun and ultraviolet light exposure; use appropriate sun protection. Post-transplant lymphoproliferative disorder related to EBV infection has been reported in immunosuppressed organ transplant patients; risk highest in young children; use combination immunosuppressant therapy with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity: Nephrotoxicity may occur when used in high doses, in patients with impaired renal function, or with other nephrotoxic drugs (eg, sirolimus, cyclosporine).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: Neurotoxicity may occur especially when used in high doses; tremor, headache, coma, and delirium have been reported and are associated with serum concentrations. Seizures may also occur. Posterior reversible encephalopathy syndrome (PRES) may also occur; symptoms (altered mental status, headache, hypertension, seizures, and visual disturbances) are reversible with dose reduction or discontinuation of therapy; stabilize blood pressure and reduce dose with suspected or confirmed PRES diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pure red cell aplasia (PRCA): PRCA has been reported in patients receiving tacrolimus. Use with caution in patients with risk factors for PRCA including parvovirus B19 infection, underlying disease, or use of concomitant medications associated with PRCA (eg, mycophenolate). Discontinuation of therapy should be considered with diagnosis of PRCA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular: Myocardial hypertrophy has been reported; may be reversible with dose reduction or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution; utilize lowest recommended I.V. or oral dose; additional dose reductions may be necessary; severe hepatic impairment (Child-Pugh score &ge;10) may require decreased dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension; mild-to-moderate hypertension may occur (severe hypertension is rare); antihypertensive treatment may be necessary; avoid use of potassium-sparing diuretics due to risk of hyperkalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Due to potential for further nephrotoxicity, utilize lowest recommended I.V. or oral dose; additional dose reductions may be necessary. Delay initiation of therapy in kidney transplant patients if postoperative oliguria occurs; begin therapy no sooner than 6 hours and within 24 hours post-transplant, but may be delayed until renal function has recovered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug/drug-food interactions: Potentially  significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Everolimus combination therapy: In liver transplantation, the tacrolimus dose and target range should be reduced to minimize the risk of nephrotoxicity when used in combination with everolimus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: Each mL of injection contains polyoxyl 60 hydrogenated castor oil (HCO-60) (200 mg) and dehydrated alcohol USP 80% v/v. Anaphylaxis has been reported with the injection, use should be reserved for those patients not able to take oral medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of a physician experienced in immunosuppressive therapy and organ transplantation in a facility appropriate for monitoring and managing therapy.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should not be immunized with live vaccines during or shortly after treatment and should avoid close contact with recently vaccinated (live vaccine) individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose intolerance: Oral formulations contain lactose; the Canadian labeling does not recommend use of these products in patients who may be lactose intolerant  (eg, Lapp lactase deficiency, glucose-galactose malabsorption, galactose intolerance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring of concentrations: Closely monitor tacrolimus levels to assist in dose adjustment, monitor compliance, prevent organ rejection, and reduce drug-related toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9564168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9564169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): May decrease the metabolism of Tacrolimus (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     TraZODone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus doses will need to be substantially reduced, and the tacrolimus dosing interval will likely need to be prolonged with concurrent boceprevir. Follow tacrolimus concentrations closely and monitor patients for evidence of tacrolimus toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May increase the serum concentration of Tacrolimus (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Tacrolimus (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: May decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor tacrolimus concentrations and response closely following initiation and/or discontinuation of chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clotrimazole (Oral): May increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Tacrolimus (Systemic) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Tacrolimus (Systemic). Management: Closely monitor tacrolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of tacrolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ertapenem: May increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: Tacrolimus (Systemic) may enhance the nephrotoxic effect of Fenofibrate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: Tacrolimus (Systemic) may enhance the nephrotoxic effect of Fenofibric Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Tacrolimus (Systemic). Management: Monitor tacrolimus concentrations closely and adjust dose as necessary when concomitantly administered with fluconazole.  Reduced doses of fluconazole will likely be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: Monitor tacrolimus concentrations closely and adjust dose as necessary when concomitantly administered with itraconazole. Tacrolimus dose reductions will likely be required. The magnitude of this interaction may be greater in older patients.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose adjustment may be required when taken with ketoconazole due to elevated plasma concentrations of tacrolimus.  Monitor tacrolimus concentrations and clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Tacrolimus (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May decrease the metabolism of Calcineurin Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Tacrolimus (Systemic). Mifepristone may increase the serum concentration of Tacrolimus (Systemic). Management: Avoid tacrolimus during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: Reduce tacrolimus dose to approximately one-third of original dose when starting posaconazole. Tacrolimus blood concentrations should be monitored closely during and at discontinuation of posaconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pantoprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: May increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Tacrolimus (Systemic) may enhance the adverse/toxic effect of Sirolimus. Sirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Sirolimus may decrease the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus and sirolimus should only be used concomitantly as part of a protocol with a known risk:benefit profile and an established safety record.  Several regimens combining these agents have been associated with excess morbidity and/or mortality.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Tacrolimus (Systemic). Management: Significant tacrolimus dose reductions are likely to be required if used with telaprevir.  Concurrent use should be performed with great caution and close monitoring of both tacrolimus concentrations and clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Tacrolimus (Systemic) may enhance the adverse/toxic effect of Temsirolimus. Temsirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Temsirolimus may decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: When starting voriconazole in patients already receiving tacrolimus, reduce tacrolimus dose to one-third of the original dose. Monitor tacrolimus blood levels closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9564173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food decreases rate and extent of absorption. High-fat meals have most pronounced effect (37% decrease in AUC, 77% decrease in C",
"     <sub>",
"      max",
"     </sub>",
"     ). Grapefruit juice, a CYP3A4 inhibitor, may increase serum level and/or toxicity of tacrolimus. Management: Administer with or without food, but be consistent. Avoid concurrent use of grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may reduce tacrolimus serum concentrations. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9559521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9559522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Tacrolimus crosses the human placenta and is measurable in the cord blood, amniotic fluid, and newborn serum. Tacrolimus concentrations in the placenta may be higher than the maternal serum. No consistent pattern of congenital anomalies has been observed. Transient neonatal hyperkalemia and renal dysfunction have been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The National Transplantation Pregnancy Registry (NTPR, Temple University) is a registry for pregnant women taking immunosuppressants following any solid organ transplant. The NTPR encourages reporting of all immunosuppressant exposures during pregnancy in transplant recipients at 877-955-6877.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9559524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9559525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concentrations of tacrolimus in breast milk are lower than that of the maternal serum. The low bioavailability of tacrolimus following oral absorption may also decrease the amount of exposure to a nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9564222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsule: Administer with or without food; be consistent with timing and composition of meals, food decreases bioavailability. Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9564279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Hecoria Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $218.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $436.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $2180.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Prograf Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $237.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $475.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $2378.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Tacrolimus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $222.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $445.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $2229.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Prograf Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (1 mL): $163.94",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9564239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function, hepatic function, serum electrolytes (especially potassium), glucose and blood pressure, measure 3 times/week for first few weeks, then gradually decrease frequency as patient stabilizes. Whole blood concentrations should be used for monitoring (trough for oral therapy). Signs/symptoms of anaphylactic reactions during infusion should also be monitored. Patients should be monitored during the first 30 minutes of the infusion, and frequently thereafter.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Tacrolimus serum levels may be falsely elevated in infected liver transplant patients due to interference from &beta;-galactosidase antibodies.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F9564191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Heart transplant: Typical whole blood trough concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Months 1-3: 10-20 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Months &ge;4: 5-15 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kidney transplant: Whole blood trough concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     In combination with azathioprine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Months 1-3: 7-20 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Months 4-12: 5-15 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     In combination with mycophenolate mofetil/IL-2 receptor antagonist (eg, daclizumab): Months 1-12: 4-11 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liver transplant: Whole blood trough concentrations: Months 1-12: 5-20 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Recommended therapeutic ranges when administered in combination with everolimus for liver transplant (Zortress&reg; product labeling, 2013):",
"     </i>",
"     By 3 weeks after first everolimus dose and through month 12 post-transplant: 3-5 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of graft-versus-host disease (unlabeled use): 10-20 ng/mL (Uberti, 1999) although some institutions use a lower limit of 5 ng/mL and an upper limit of 15 ng/mL (Przepiorka, 1999; Yanik, 2000)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adoport (GB);",
"     </li>",
"     <li>",
"      Advagraf (BE, CL, CZ, DE, DK, EE, FR, GB, HK, IE, SE, TH, TW);",
"     </li>",
"     <li>",
"      Capexion (GB);",
"     </li>",
"     <li>",
"      Modigraf (GB);",
"     </li>",
"     <li>",
"      Pangraf (IN);",
"     </li>",
"     <li>",
"      Prograf (AE, AR, AT, AU, BE, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IQ, IR, IT, JO, JP, KP, KW, LB, LY, MY, NI, NZ, OM, PA, PE, PH, PL, PY, QA, RU, SA, SE, SG, SV, SY, TH, TR, TW, UY, VE, YE);",
"     </li>",
"     <li>",
"      Prograf XL (AU, CO);",
"     </li>",
"     <li>",
"      Tacrobell (KP);",
"     </li>",
"     <li>",
"      Tacrocin (PH);",
"     </li>",
"     <li>",
"      Tagraf (PH);",
"     </li>",
"     <li>",
"      Tarimus (KP);",
"     </li>",
"     <li>",
"      Vingraf (PH);",
"     </li>",
"     <li>",
"      Vivadex (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9564189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppresses cellular immunity (inhibits T-lymphocyte activation), by binding to an intracellular protein, FKBP-12 and complexes with calcineurin dependent proteins to inhibit calcineurin phosphatase activity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9564197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Better in resected patients with a closed stoma; unlike cyclosporine, clamping of the T-tube in liver transplant patients does not alter trough concentrations or AUC; Oral: Incomplete and variable; the rate and extent of absorption is affected by food and may be most pronounced with a high-fat meal. Oral absorption may be variable in stem cell transplant patients with mucositis due to the conditioning regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 0.5-4.7 L/kg; Adults: 0.55-2.47 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~99% primarily to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP3A4 to eight possible metabolites (major metabolite, 31-demethyl tacrolimus, shows same activity as tacrolimus",
"     <i>",
"      in vitro",
"     </i>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Children: 7% to 55%, Adults: 7% to 32%; Absolute: Unknown",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Variable, 23-46 hours in healthy volunteers; 2.1-36 hours in transplant patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 0.5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~93%); urine (&lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Asante-Korang A, Boyle GJ, Webber SA, et al, &ldquo;Experience of FK506 Immune Suppression in Pediatric Heart Transplantation: A Study of Long-Term Adverse Effects,&rdquo;",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 1996, 15(4):415-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/8732602/pubmed\" id=\"8732602\" target=\"_blank\">",
"        8732602",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Atkison P, Joubert G, Barron A, et al, &ldquo;Hypertrophic Cardiomyopathy Associated With Tacrolimus in Paediatric Transplant Patients,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 345(8954):894-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/7535875/pubmed\" id=\"7535875\" target=\"_blank\">",
"        7535875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bronster DJ, Yonover P, Stein J, et al, &ldquo;Demyelinating Sensorimotor Polyneuropathy After Administration of FK506,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1995, 59(7):1066-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/7535959/pubmed\" id=\"7535959\" target=\"_blank\">",
"        7535959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cerra FB and Gruber SA, &ldquo;Critical Care of the Transplant Patient,&rdquo;",
"      <i>",
"       Crit Care Clin",
"      </i>",
"      , 1990, 6(4):813-1034.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/2265380/pubmed\" id=\"2265380\" target=\"_blank\">",
"        2265380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      French AE, Soldin SJ, Soldin OP, et al, &ldquo;Milk Transfer and Neonatal Safety of Tacrolimus,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(6):815-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/12773068/pubmed\" id=\"12773068\" target=\"_blank\">",
"        12773068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furlan V, Perello L, Jacquemin E, et al, &ldquo;Interactions Between FK506 and Rifampicin or Erythromycin in Pediatric Liver Recipients,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1995, 59(8):1217-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/7537398/pubmed\" id=\"7537398\" target=\"_blank\">",
"        7537398",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furlong T, Storb R, Anasetti C, et al, &ldquo;Clinical Outcome After Conversion to FK 506 (Tacrolimus) Therapy for Acute Graft-Versus-Host Disease Resistant to Cyclosporine or for Cyclosporine-Associated Toxicities,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2000, 26(9):985-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/11100278/pubmed\" id=\"11100278\" target=\"_blank\">",
"        11100278",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardiner SJ and Begg EJ, &ldquo;Breastfeeding During Tacrolimus Therapy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2006, 107(2 Pt 2):453-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/16449146/pubmed\" id=\"16449146\" target=\"_blank\">",
"        16449146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grimer M and Caring for Australians with Renal Impairment (CARI), &ldquo;The CARI Guidelines. Calcineurin Inhibitors in Renal Transplantation: Pregnancy, Lactation and Calcineurin Inhibitors,&rdquo; Nephrology (Carlton), 2007, 12(Suppl 1):98-105.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/17316288/pubmed\" id=\"17316288\" target=\"_blank\">",
"        17316288",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hodak SP, Moubarak JB, Rodriguez I, et al, &ldquo;QT Prolongation and Near Fatal Cardiac Arrhythmia After Intravenous Tacrolimus Administration: A Case Report,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1998, 66(4):535-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/9734501/pubmed\" id=\"9734501\" target=\"_blank\">",
"        9734501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jain A, Venkataramanan R, Fung JJ, et al, &ldquo;Pregnancy After Liver Transplantation Under Tacrolimus,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1997, 64(4):559-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/9293865/pubmed\" id=\"9293865\" target=\"_blank\">",
"        9293865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson MC, So S, March JW, et al, &ldquo;QT Prolongation and Torsades de Pointes After Administration of FK506,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1992, 53(4):929-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/1373538/pubmed\" id=\"1373538\" target=\"_blank\">",
"        1373538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jusko WJ, Piekoszewski W, Klintmalm GB, et al, &ldquo;Pharmacokinetics of Tacrolimus in Liver Transplant Patients,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57(3):281-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/7535213/pubmed\" id=\"7535213\" target=\"_blank\">",
"        7535213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kainz A, Harabacz I, Cowlrick IS, et al, &ldquo;Analysis of 100 Pregnancy Outcomes in Women Treated Systemically With Tacrolimus,&rdquo;",
"      <i>",
"       Transpl Int",
"      </i>",
"      , 2000, 13(Suppl 1):299-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/11112018/pubmed\" id=\"11112018\" target=\"_blank\">",
"        11112018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufman DB, Kaplan B, Kanwar YS, et al, &ldquo;The Successful Use of Tacrolimus (FK506) in a Pancreas/Kidney Transplant Recipient With Recurrent Cyclosporine-Associated Hemolytic Uremic Syndrome,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1995, 59(12):1737-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/7541579/pubmed\" id=\"7541579\" target=\"_blank\">",
"        7541579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly PA, Burckart GJ, and Venkataramanan R, &ldquo;Tacrolimus: A New Immunosuppressive Agent,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(14):1521-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/7552894/pubmed\" id=\"7552894\" target=\"_blank\">",
"        7552894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knorr JP, Grewal KS, Balasubramanian M, et al, &ldquo;Falsely Elevated Tacrolimus Levels Caused by Immunoassay Interference Secondary to Beta-Galactosidase Antibodies in an Infected Liver Transplant Recipient,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010, 30(9):954.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/20812435/pubmed\" id=\"20812435\" target=\"_blank\">",
"        20812435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacDonald AS and Sketris IS, &ldquo;Tacrolimus in Transplantation,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(14):1569-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/7552906/pubmed\" id=\"7552906\" target=\"_blank\">",
"        7552906",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDiarmid SV, Colonna JO, Shaked A, et al, &ldquo;Differences in Oral FK506 Dose Requirements Between Adults and Pediatric Liver Transplant Patients,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1993, 55(6):1328-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/7685933/pubmed\" id=\"7685933\" target=\"_blank\">",
"        7685933",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Menegaux F, Keeffe EB, Andrews BT, et al, &ldquo;Neurological Complications of Liver Transplantation in Adult Versus Pediatric Patients,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1994, 58(4):447-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/8073514/pubmed\" id=\"8073514\" target=\"_blank\">",
"        8073514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Messina C, Faraci M, de Fazio V, et al, &ldquo;Paediatric Working Party. Prevention and Treatment of Acute GvHD,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2008, 41(Suppl 2):65-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/18545247/pubmed\" id=\"18545247\" target=\"_blank\">",
"        18545247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Minematsu T, Ohtani H, Sato H, et al, &ldquo;Sustained QT Prolongation Induced by Tacrolimus in Guinea Pigs,&rdquo;",
"      <i>",
"       Life Sci",
"      </i>",
"      , 1999, 65(14):PL197-202.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/10530807/pubmed\" id=\"10530807\" target=\"_blank\">",
"        10530807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Natazuka T, Ogawa R, Kizaki T, et al, &ldquo;Immunosuppressive Drugs and Hypertrophic Cardiomyopathy,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 345(8965):1644.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/7540241/pubmed\" id=\"7540241\" target=\"_blank\">",
"        7540241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Podesser BK, Rinaldi M, Yona NA, et al, &ldquo;Comparison of Low and High Initial Tacrolimus Dosing in Primary Heart Transplant Recipients: A Prospective European Multicenter Study,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2005, 79(1):65-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/15714171/pubmed\" id=\"15714171\" target=\"_blank\">",
"        15714171",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Przepiorka D, Devine S, Fay J, et al, &ldquo;Practical Considerations in the Use of Tacrolimus for Allogeneic Marrow Transplantation,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 1999, 24(10):1053-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/10578154/pubmed\" id=\"10578154\" target=\"_blank\">",
"        10578154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Przepiorka D, Suzuki J, Ippoliti C, et al, &ldquo;Blood Tacrolimus Concentration Unchanged by Plasmapheresis,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1994, 51(13):1708.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/7524318/pubmed\" id=\"7524318\" target=\"_blank\">",
"        7524318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starzl TE, Fung J, Jordan M, et al, &ldquo;Kidney Transplantation Under FK506,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(1):63-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/1693970/pubmed\" id=\"1693970\" target=\"_blank\">",
"        1693970",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Uberti JP, Cronin S, and Ratanatharathorn V, &ldquo;Optimum Use of Tacrolimus in the Prophylaxis of Graft Versus Host Disease,&rdquo;",
"      <i>",
"       BioDrugs",
"      </i>",
"      ,  1999, 11(5):343-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/18031144/pubmed\" id=\"18031144\" target=\"_blank\">",
"        18031144",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winkel E, DiSesa VJ, and Costanzo MR, &ldquo;Advances in Heart Transplantation,&rdquo;",
"      <i>",
"       Dis Mon",
"      </i>",
"      , 1999, 45(3):62-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/10080968/pubmed\" id=\"10080968\" target=\"_blank\">",
"        10080968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winkler M and Christians U, &ldquo;A Risk-Benefit Assessment of Tacrolimus in Transplantation,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):348-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/7545405/pubmed\" id=\"7545405\" target=\"_blank\">",
"        7545405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yanik G, Levine JE, Ratanatharathorn V, et al, &ldquo;Tacrolimus (FK506) and Methotrexate as Prophylaxis for Acute Graft-Versus-Host Disease in Pediatric Allogeneic Stem Cell Transplantation,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2000, 26(2):161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/42/4778/abstract-text/10918426/pubmed\" id=\"10918426\" target=\"_blank\">",
"        10918426",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9920 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4778=[""].join("\n");
var outline_f4_42_4778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559505\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559510\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559511\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564525\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564218\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564217\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564219\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564220\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564221\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564277\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13262301\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559517\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559509\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564223\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564188\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559518\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559520\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559508\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559543\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559526\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559527\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564168\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564169\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564173\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559521\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559522\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559524\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559525\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564222\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564279\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564239\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564191\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390236\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564189\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564197\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9920\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9920|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/14/40165?source=related_link\">",
"      Tacrolimus (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/51/4921?source=related_link\">",
"      Tacrolimus (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/30/6630?source=related_link\">",
"      Tacrolimus (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/21/341?source=related_link\">",
"      Tacrolimus (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/9/26772?source=related_link\">",
"      Tacrolimus (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_42_4779="Pressure versus transit";
var content_f4_42_4779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Esophageal motility abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abnormal pressure and transit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Achalasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scleroderma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ineffective esophageal motility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal esophageal spasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abnormal pressure only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutcracker esophagus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertensive LES",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotensive LES",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poorly relaxing LES",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4779=[""].join("\n");
var outline_f4_42_4779=null;
var title_f4_42_4780="Survival rates following resection of a pancreatic neuroendocrine tumor";
var content_f4_42_4780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Five- and ten-year survival rates for patients who underwent resection of a pancreatic neuroendocrine tumor",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Observed survival*",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Relative survival&bull;",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Median survival, months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       5-year, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       10-year, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       5-year, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       10-year, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       I",
"      </td>",
"      <td>",
"       61.0",
"      </td>",
"      <td>",
"       46.0",
"      </td>",
"      <td>",
"       75.6",
"      </td>",
"      <td>",
"       71.1",
"      </td>",
"      <td>",
"       112",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       II",
"      </td>",
"      <td>",
"       52.0",
"      </td>",
"      <td>",
"       28.8",
"      </td>",
"      <td>",
"       64.3",
"      </td>",
"      <td>",
"       45.8",
"      </td>",
"      <td>",
"       63",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       III",
"      </td>",
"      <td>",
"       41.4",
"      </td>",
"      <td>",
"       18.5",
"      </td>",
"      <td>",
"       60.5",
"      </td>",
"      <td>",
"       33.1",
"      </td>",
"      <td>",
"       46",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       15.5",
"      </td>",
"      <td>",
"       5.1",
"      </td>",
"      <td>",
"       19.9",
"      </td>",
"      <td>",
"       8.9",
"      </td>",
"      <td>",
"       14",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Comparisons between each stage group are significant to p &lt;0.0001.",
"     <br>",
"      &bull; Survival adjusted for patient age by matching against 1990 United States Census Bureau data.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Bilimoria KY, Bentrem DJ, Merkow RP, et al: Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007; 205:558.",
"       </li>",
"      </ol>",
"      Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4780=[""].join("\n");
var outline_f4_42_4780=null;
var title_f4_42_4781="Differential diagnosis of physical findings sexual abuse 1";
var content_f4_42_4781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of physical findings in the evaluation of childhood sexual abuse (part 1)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Finding",
"      </td>",
"      <td class=\"subtitle1\">",
"       Differential diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Perineal area (boys or girls)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Perineal inflammation or erythema",
"      </td>",
"      <td>",
"       Candidal infection, pinworms, perianal cellulitis, contact dermatitis, atopic dermatitis, psoriasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Perineal ulcer or vesicular rash*",
"      </td>",
"      <td>",
"       Syphilis, herpes simplex virus, varicella, chanchroid, Behcet's disease, bullous pemphigoid, Epstein-Barr virus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Perineal bruising",
"      </td>",
"      <td>",
"       Mongolian spots, trauma, hemolytic uremic syndrome, Henoch-Schonlein purpura",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Perianal area (boys or girls)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Perianal erythema",
"      </td>",
"      <td>",
"       Encopresis, poor hygiene, pinworms, Group A streptococcal or staphylococcal infection, irritants, trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Anal fissures",
"      </td>",
"      <td>",
"       Constipation; perianal irritation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Perianal scar",
"      </td>",
"      <td>",
"       May be caused by medical conditions, such as fissures, or lesions of Crohn's disease, or from previous medical procedures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Venous congestion or pooling",
"      </td>",
"      <td>",
"       Usually due to positioning of child; may be seen in constipation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Flattened anal folds",
"      </td>",
"      <td>",
"       May be caused by relaxation of the anal sphincter or swelling of the perianal tissues from infection or trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Anogenital warts&bull;",
"      </td>",
"      <td>",
"       Human papillomavirus, molluscum contagiousum, common warts, skin tags",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rectal bleeding",
"      </td>",
"      <td>",
"       Hemorrhoids, Crohn's disease, rectal prolapse, rectal tumors; anal trauma or penetration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Anal dilation to less than 2 cm, with or without stool present",
"      </td>",
"      <td>",
"       May be a normal reflex or caused by severe constipation or encopresis, sedation, anesthesia, neuromuscular conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Male genitalia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Penile trauma",
"      </td>",
"      <td>",
"       <p>",
"        Hair tourniquet, zipper entrapment injury, straddle injury",
"       </p>",
"       <p>",
"        (history is usually readily available for zipper entrapment and",
"       </p>",
"       <p>",
"        straddle injuries; straddle injuries usually affect the anterior",
"       </p>",
"       <p>",
"        structures)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Penile or scrotal erythema",
"      </td>",
"      <td>",
"       Irritants, infection, trauma",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Cultures for herpes simplex virus type 1 and 2 and syphilis should be obtained.",
"     <br>",
"      <br>",
"       &bull; May need biopsy to confirm diagnosis.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bays, J, Jenny, C. Genital and",
"     <br>",
"      anal conditions confused with child sexual abuse trauma. Am J Dis Child",
"      <br>",
"       1990; 144:1319. Hymel, KP, Jenny, C. Child sexual abuse. Pediatr Rev",
"       <br>",
"        1996; 17:236. Adams, JA. Evolution of a classification scale: medical",
"        <br>",
"         evaluation of suspected child sexual abuse. Child Maltreat 2001; 6:31.",
"         <br>",
"          Adams, JA. Medical evaluation of suspected child sexual abuse. J",
"          <br>",
"           Pediatr Adolesc Gynecol 2004; 17:191.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4781=[""].join("\n");
var outline_f4_42_4781=null;
var title_f4_42_4782="Contents: Trauma surgery";
var content_f4_42_4782=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Trauma surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Trauma surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Abdominal trauma management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/47/22266\">",
"           Management of duodenal and pancreatic trauma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/17/9497\">",
"           Management of hepatic trauma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/4/1097\">",
"           Management of the open abdomen in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/22/28009\">",
"           Recognition and management of diaphragmatic injury in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/11/29880\">",
"           Surgical techniques for managing hepatic injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/57/26522\">",
"           Traumatic gastrointestinal injury in the adult patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Basic principles of trauma management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/44/23242\">",
"           Coagulopathy associated with trauma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Extremity trauma management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/57/12186\">",
"           Severe extremity injury in the adult patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/40/19082\">",
"           Surgical management of severe extremity injury",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pelvic trauma management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/16/25865\">",
"           Severe pelvic fracture in the adult trauma patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thoracic trauma management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/6/19562\">",
"           Inpatient management of traumatic rib fractures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma critical care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/54/1898\">",
"           Management of splenic injury in the adult trauma patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/21/31066\">",
"           Overview of inpatient management in the adult trauma patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/3/31801\">",
"           Resuscitative thoracotomy: technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/56/7049\">",
"           Surgical management of splenic injury in the adult trauma patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular trauma management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/16/266\">",
"           Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/47/8953\">",
"           Blunt cerebrovascular injury: Treatment and outcomes",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-409196CE2E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f4_42_4782=[""].join("\n");
var outline_f4_42_4782=null;
var title_f4_42_4783="Rel risk disease increase wt";
var content_f4_42_4783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adult weight change and the risk of disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 512px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Even a modest increase in weight as an adult is associated with an increased risk of type 2 diabetes, hypertension, coronary heart disease, and cholelithiasis. Panel A shows data for women in the Nurses' Health Study, initially 30 to 55 years of age, who were followed for up to 18 years. Panel B shows data for men in the Health Professionals Follow-up Study, initially 40 to 65 years of age, who were followed for up to 10 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341:427.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_42_4783=[""].join("\n");
var outline_f4_42_4783=null;
